ID

DB00250|APRD00345||

名称

Dapsone

描述

A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)

cas号

80-08-0

唯一标识码

8W5C518302

状态

solid

组

approved,investigational,

指示

For the treatment and management of leprosy and dermatitis herpetiformis.

药效学

Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation.

作用机制

Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood.

毒性

Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.

代谢

Hepatic, mostly CYP2E1-mediated.

吸收

Bioavailability is 70 to 80% following oral administration.

半衰期

28 hours (range 10-50 hours)

分类

description:This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.
direct-parent:Benzenesulfonyl compounds
kingdom:Organic compounds
superclass:Benzenoids
class:Benzene and substituted derivatives
subclass:Benzenesulfonyl compounds
alternative-parent:Aniline and substituted anilines
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic oxides
alternative-parent:Organopnictogen compounds
alternative-parent:Primary amines
alternative-parent:Sulfones
substituent:Amine
substituent:Aniline or substituted anilines
substituent:Aromatic homomonocyclic compound
substituent:Benzenesulfonyl group
substituent:Hydrocarbon derivative
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organopnictogen compound
substituent:Organosulfur compound
substituent:Primary amine
substituent:Sulfone
substituent:Sulfonyl

消除途径

Renal

种类

Anti-Acne Preparations

Anti-Acne Preparations for Topical Use

Anti-Bacterial Agents
D000900
Anti-Infective Agents
D000890
Antibiotics for Pneumocystis Pneumonia

Antiinfectives for Systemic Use

Antimalarials
D000962
Antimycobacterials

Antiparasitic Agents
D000977
Antiprotozoals
D000981
Cytochrome P-450 CYP2C18 Substrates

Cytochrome P-450 CYP2C19 Substrates

Cytochrome P-450 CYP2C8 Substrates

Cytochrome P-450 CYP2C9 Inducers
D065698
Cytochrome P-450 CYP2C9 Inducers (strength unknown)

Cytochrome P-450 CYP2C9 Substrates

Cytochrome P-450 CYP2E1 Substrates

Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 CYP3A5 Substrates

Cytochrome P-450 CYP3A7 Substrates

Cytochrome P-450 Enzyme Inducers
D065693
Cytochrome P-450 Substrates

Dermatologicals
D003879
Drugs causing inadvertant photosensitivity

Drugs for Treatment of Lepra

Enzyme Inhibitors
D004791
Folic Acid Antagonists
D005493
Leprostatic Agents
D007917
Methemoglobinemia Associated Agents

Miscellaneous Antimycobacterials

Miscellaneous Local Anti-infectives

Photosensitizing Agents
D017319
Sulfones
D013450
Sulfur Compounds
D013457

盐类

蛋白质结合

70 to 90%

清除

同义词

language:english; code:; name;1,1'-sulfonylbis(4-aminobenzene)
language:english; code:; name;1,1'-Sulfonylbis[4-aminobenzene]
language:english; code:; name;4-(4-amino-benzenesulfonyl)-phenylamine
language:english; code:; name;4-(4-aminophenylsulfonyl)aniline
language:english; code:; name;4-(4-aminophenylsulfonyl)benzenamine
language:english; code:; name;4-aminophenyl sulfone
language:english; code:; name;4,4'-dapsone
language:english; code:; name;4,4'-diaminodiphenyl sulfone
language:english; code:; name;4,4'-Diaminodiphenyl sulphone
language:english; code:; name;4,4'-Diaminodiphenylsulfone
language:english; code:; name;4,4'-sulfonylbisaniline
language:english; code:; name;4,4'-Sulfonylbisbenzenamine
language:english; code:; name;4,4'-Sulfonylbisbenzeneamine
language:english; code:; name;4,4'-Sulfonyldianilin
language:english; code:iupac; name;4,4'-sulfonyldianiline
language:english; code:; name;bis(4-aminophenyl)sulfone
language:english; code:; name;Bis(p-aminophenyl) sulfone
language:english; code:; name;DADPS
language:spanish; code:inn; name;Dapsona
language:english; code:inn/usan; name;Dapsone
language:latin; code:inn; name;Dapsonum
language:english; code:; name;DDS
language:english; code:; name;Diaphenylsulfone
language:english; code:; name;p-aminophenyl sulfone
language:english; code:; name;p,p-sulphonylbisbenzamine
language:english; code:; name;p,p-sulphonylbisbenzenamine
language:english; code:; name;p,p'-diaminodiphenyl sulfone

国际品牌

配送量

产品

name:011503 Dapsone 6% / Niacinamide 2% / Spironolactone 5%
labeller:Sincerus Florida, LLC
ndc-id:
ndc-product-code:72934-1211
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-02
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:011504 Dapsone 8.5% / Niacinamide 4%
labeller:Sincerus Florida, LLC
ndc-id:
ndc-product-code:72934-1212
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-02
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Aczone
labeller:Qlt Inc.
ndc-id:
ndc-product-code:0469-5005
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2007-09-04
ended-marketing-on:
dosage-form:Gel
strength:50 mg/1g
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aczone
labeller:Almirall, LLC
ndc-id:
ndc-product-code:16110-526
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-09-10
ended-marketing-on:
dosage-form:Gel
strength:75 mg/1g
route:Topical
fda-application-number:NDA207154
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aczone
labeller:Allergan, Inc.
ndc-id:
ndc-product-code:0023-3670
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-06-24
ended-marketing-on:
dosage-form:Gel
strength:50 mg/1g
route:Topical
fda-application-number:NDA021794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Aczone
labeller:Bausch Health, Canada Inc.
ndc-id:
ndc-product-code:
dpd-id:02281074
ema-product-code:
ema-ma-number:
started-marketing-on:2011-10-21
ended-marketing-on:
dosage-form:Gel
strength:5 %
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Aczone 7.5
labeller:Allergan, Inc.
ndc-id:
ndc-product-code:0023-5206
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-02-26
ended-marketing-on:
dosage-form:Gel
strength:75 mg/1g
route:Topical
fda-application-number:NDA207154
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avlosulfon Tab 100mg
labeller:Ayerst Laboratories
ndc-id:
ndc-product-code:
dpd-id:00002526
ema-product-code:
ema-ma-number:
started-marketing-on:1971-12-31
ended-marketing-on:1996-09-10
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Dapsone
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-2817
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-04-22
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA086841
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-3801
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2005-12-16
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA086842
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Remedy Repack
ndc-id:
ndc-product-code:49349-078
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-11-18
ended-marketing-on:2011-11-19
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA086841
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Fera Pharmaceuticals
ndc-id:
ndc-product-code:48102-019
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-04-01
ended-marketing-on:2016-04-01
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA205429
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Fera Pharmaceuticals
ndc-id:
ndc-product-code:48102-020
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-04-01
ended-marketing-on:2016-04-01
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA205429
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Department Of State Health Services, Pharmacy Branch
ndc-id:
ndc-product-code:55695-025
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-08-15
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA086842
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Department Of State Health Services, Pharmacy Branch
ndc-id:
ndc-product-code:55695-005
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2008-08-15
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA086841
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Carilion Materials Management
ndc-id:
ndc-product-code:68151-2693
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-04
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA086841
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:43353-222
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-01
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Aphena Pharma Solutions Tennessee, Inc.
ndc-id:
ndc-product-code:43353-223
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-01
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA204074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Av Kare, Inc.
ndc-id:
ndc-product-code:42291-298
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-17
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Av Kare, Inc.
ndc-id:
ndc-product-code:42291-299
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-17
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA204074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Novitium Pharma Llc
ndc-id:
ndc-product-code:70954-135
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-15
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA206505
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Novitium Pharma Llc
ndc-id:
ndc-product-code:70954-136
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-15
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA206505
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Marlex Pharmaceuticals Inc
ndc-id:
ndc-product-code:10135-654
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-05-01
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA206505
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Marlex Pharmaceuticals Inc
ndc-id:
ndc-product-code:10135-655
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-05-01
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA206505
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-1387
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-16
ended-marketing-on:
dosage-form:Gel
strength:50 mg/1g
route:Topical
fda-application-number:ANDA209506
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Jacobus Pharmaceutical Company, Inc.
ndc-id:
ndc-product-code:49938-102
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1979-07-03
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA086841
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Jacobus Pharmaceutical Company, Inc.
ndc-id:
ndc-product-code:49938-101
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1979-07-03
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA086842
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Pacific Pharma, Inc.
ndc-id:
ndc-product-code:60758-670
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-18
ended-marketing-on:
dosage-form:Gel
strength:50 mg/1g
route:Topical
fda-application-number:NDA021794
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-4197
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-03-01
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA209430
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-4198
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-03-01
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA209430
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Nostrum Laboratories, Inc.
ndc-id:
ndc-product-code:29033-037
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-09
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA203887
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Nostrum Laboratories, Inc.
ndc-id:
ndc-product-code:29033-036
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-09
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA203887
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:NorthStar Rx LLC
ndc-id:
ndc-product-code:16714-956
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-16
ended-marketing-on:
dosage-form:Gel
strength:50 mg/1g
route:Topical
fda-application-number:ANDA209506
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Alvogen Inc.
ndc-id:
ndc-product-code:47781-333
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-13
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA205429
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Alvogen Inc.
ndc-id:
ndc-product-code:47781-334
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-13
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA205429
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-1388
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-06-26
ended-marketing-on:
dosage-form:Gel
strength:75 mg/1g
route:Topical
fda-application-number:ANDA210191
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-7019
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-15
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA206505
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-7018
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-15
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA206505
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-496
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-06
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA203887
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-495
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-05-06
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA203887
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Virtus Pharmaceuticals
ndc-id:
ndc-product-code:69543-150
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-01
ended-marketing-on:2021-10-31
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA204074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Virtus Pharmaceuticals
ndc-id:
ndc-product-code:69543-151
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-06-01
ended-marketing-on:2021-10-31
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA204074
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Taro Pharmaceuticals U.S.A., Inc.
ndc-id:
ndc-product-code:51672-5307
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-01-01
ended-marketing-on:
dosage-form:Gel
strength:75 mg/1g
route:Topical
fda-application-number:NDA207154
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Seton Pharmaceuticals
ndc-id:
ndc-product-code:13925-504
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-04
ended-marketing-on:
dosage-form:Tablet
strength:25 mg/1
route:Oral
fda-application-number:ANDA086841
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Seton Pharmaceuticals
ndc-id:
ndc-product-code:13925-505
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-10
ended-marketing-on:
dosage-form:Tablet
strength:100 mg/1
route:Oral
fda-application-number:ANDA086842
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Dapsone
labeller:Jacobus Pharmaceutical Company, Inc.
ndc-id:
ndc-product-code:
dpd-id:02041510
ema-product-code:
ema-ma-number:
started-marketing-on:1994-12-31
ended-marketing-on:
dosage-form:Tablet
strength:100 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Dapsone 6% / Niacinamide 2% / Spironolactone 5%
labeller:Sincerus Florida, LLC
ndc-id:
ndc-product-code:72934-1061
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-11
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dapsone 6% / Niacinamide 2% / Tretinoin 0.025%
labeller:Sincerus Florida, LLC
ndc-id:
ndc-product-code:72934-1062
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-04
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dapsone 6% / Niacinamide 4%
labeller:Sincerus Florida, LLC
ndc-id:
ndc-product-code:72934-1063
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-01
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dapsone 8.5% / Niacinamide 2% / Spironolactone 5%
labeller:Sincerus Florida, LLC
ndc-id:
ndc-product-code:72934-1064
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-10
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dapsone 8.5% / Niacinamide 2% / Tretinoin 0.025%
labeller:Sincerus Florida LLC
ndc-id:
ndc-product-code:72934-1065
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-03
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dapsone 8.5% / Niacinamide 4%
labeller:Sincerus Florida, LLC
ndc-id:
ndc-product-code:72934-1066
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-05-01
ended-marketing-on:
dosage-form:Gel
strength:
route:Topical
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Mar-dapsone
labeller:Marcan Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02481227
ema-product-code:
ema-ma-number:
started-marketing-on:2018-11-13
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Riva-dapsone
labeller:Laboratoire Riva Inc
ndc-id:
ndc-product-code:
dpd-id:02489058
ema-product-code:
ema-ma-number:
started-marketing-on:2019-08-21
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Taro-dapsone
labeller:Taro Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:
dpd-id:02484625
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD

混合物

name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Aczone 7.5
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Aczone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone 6% / Niacinamide 4%
ingredients:Dapsone + Nicotinamide
name:Dapsone 8.5% / Niacinamide 4%
ingredients:Dapsone + Nicotinamide
name:Dapsone 8.5% / Niacinamide 2% / Tretinoin 0.025%
ingredients:Dapsone + Nicotinamide + Tretinoin
name:Dapsone 6% / Niacinamide 2% / Tretinoin 0.025%
ingredients:Dapsone + Nicotinamide + Tretinoin
name:Dapsone 8.5% / Niacinamide 2% / Spironolactone 5%
ingredients:Dapsone + Nicotinamide + Spironolactone
name:Dapsone 6% / Niacinamide 2% / Spironolactone 5%
ingredients:Dapsone + Nicotinamide + Spironolactone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Aczone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Aczone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:Dapsone
ingredients:Dapsone
name:011503 Dapsone 6% / Niacinamide 2% / Spironolactone 5%
ingredients:Dapsone + Nicotinamide + Spironolactone
name:011504 Dapsone 8.5% / Niacinamide 4%
ingredients:Dapsone + Nicotinamide
name:Dapsone
ingredients:Dapsone
name:Aczone
ingredients:Dapsone
name:Avlosulfon Tab 100mg
ingredients:Dapsone
name:Mar-dapsone
ingredients:Dapsone
name:Taro-dapsone
ingredients:Dapsone
name:Riva-dapsone
ingredients:Dapsone

包装者

name:Allergan Inc.
url:http://www.allergan.com
name:A-S Medication Solutions LLC
url:http://orders.a-smeds.com
name:Comprehensive Consultant Services Inc.
url:
name:Gallipot
url:http://www.gallipot.com
name:Jacobus Pharmaceutical Co.
url:
name:Kaiser Foundation Hospital
url:
name:Murfreesboro Pharmaceutical Nursing Supply
url:http://www.unitdosesupply.com
name:PD-Rx Pharmaceuticals Inc.
url:http://www.pdrx.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Prepak Systems Inc.
url:http://www.prepaksys.com
name:Remedy Repack
url:http://www.remedyrepack.com
name:Tolmar Inc.
url:http://www.tolmar.com

生产者

generic:是; url:; name;Jacobus pharmaceutical co

价格

Dapsone powder
5.38(单位：USD）
g
Aczone 5% gel
5.52(单位：USD）
g
Dapsone 30 25 mg tablet Box
35.99(单位：USD）
box
Dapsone 30 100 mg tablet Box
42.99(单位：USD）
box
Dapsone 25 mg tablet
0.2(单位：USD）
tablet
Dapsone 100 mg tablet
0.86(单位：USD）
tablet

受影响的生物体

MycobacteriaMycobacterium leprae

剂量

form:Gel
route:Topical
strength:5 %
form:Gel
route:Topical
strength:75 mg/1g
form:Tablet
route:Oral
strength:
form:Gel
route:Topical
strength:50 mg/1g
form:Suspension
route:Oral
strength:5 mg/1mL
form:Tablet
route:Oral
strength:100 mg/1
form:Tablet
route:Oral
strength:25 mg/1
form:Gel
route:Topical
strength:
form:Tablet, film coated
route:Oral
strength:50 mg
form:Gel
route:Topical
strength:5 g
form:Tablet
route:Oral
strength:100 mg
form:Tablet
route:Oral
strength:50 mg
form:Capsule
route:
strength:150 mg
form:Capsule
route:
strength:100 mg

atc代码

Other anti-acne preparations for topical use
ANTI-ACNE PREPARATIONS FOR TOPICAL USE
ANTI-ACNE PREPARATIONS
DERMATOLOGICALS
Drugs for treatment of lepra
DRUGS FOR TREATMENT OF LEPRA
ANTIMYCOBACTERIALS
ANTIINFECTIVES FOR SYSTEMIC USE

fda标签

//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00250.pdf?1265922803

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00250.pdf?1265922742

专利

number:2265461
country:Canada
approved:2004-11-30
expires:2017-09-10
pediatric-extension:否
number:6060085
country:United States
approved:2000-05-09
expires:2016-09-11
pediatric-extension:否
number:5863560
country:United States
approved:1999-01-26
expires:2016-09-11
pediatric-extension:否
number:6620435
country:United States
approved:2003-09-16
expires:2016-09-11
pediatric-extension:否
number:9161926
country:United States
approved:2015-10-20
expires:2033-11-18
pediatric-extension:否
number:9517219
country:United States
approved:2016-12-13
expires:2033-11-18
pediatric-extension:否

食物相互作用

Take with or without food. The absorption is unaffected by food.

药物相互作用

DB06697
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Artemether.
DB06708
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Lumefantrine.
DB01032
Probenecid may decrease the excretion rate of Dapsone which could result in a higher serum level.
DB00440
The serum concentration of Dapsone can be increased when it is combined with Trimethoprim.
DB00834
The serum concentration of Dapsone can be increased when it is combined with Mifepristone.
DB00116
The therapeutic efficacy of Dapsone can be decreased when used in combination with Tetrahydrofolic acid.
DB00158
The therapeutic efficacy of Dapsone can be decreased when used in combination with Folic acid.
DB00650
The therapeutic efficacy of Dapsone can be decreased when used in combination with Leucovorin.
DB02031
The therapeutic efficacy of Dapsone can be decreased when used in combination with (6S)-5,6,7,8-tetrahydrofolic acid.
DB02067
The therapeutic efficacy of Dapsone can be decreased when used in combination with Triglu-5-formyl-tetrahydrofolate.
DB11596
The therapeutic efficacy of Dapsone can be decreased when used in combination with Levoleucovorin.
DB04789
The therapeutic efficacy of Dapsone can be decreased when used in combination with 5-methyltetrahydrofolic acid.
DB09268
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dapsone.
DB00372
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thiethylperazine.
DB00420
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Promazine.
DB00433
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Prochlorperazine.
DB00477
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Chlorpromazine.
DB00508
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Triflupromazine.
DB00623
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Fluphenazine.
DB00679
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thioridazine.
DB00680
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Moricizine.
DB00831
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Trifluoperazine.
DB00850
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perphenazine.
DB00933
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Mesoridazine.
DB01063
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Acetophenazine.
DB01069
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Promethazine.
DB01246
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Alimemazine.
DB01403
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Methotrimeprazine.
DB01608
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Periciazine.
DB01614
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Acepromazine.
DB01615
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Aceprometazine.
DB01621
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Pipotiazine.
DB01622
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thioproperazine.
DB05687
The risk or severity of QTc prolongation can be increased when Dapsone is combined with BL-1020.
DB09000
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Cyamemazine.
DB09241
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Methylene blue.
DB11540
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Propiopromazine.
DB12710
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perazine.
DB13213
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Butaperazine.
DB13382
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Chlorproethazine.
DB13420
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Thiazinam.
DB13784
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Dixyrazine.
DB14651
The risk or severity of QTc prolongation can be increased when Dapsone is combined with Perphenazine enanthate.
DB00205
The risk or severity of adverse effects can be increased when Pyrimethamine is combined with Dapsone.
DB00358
The risk or severity of adverse effects can be increased when Mefloquine is combined with Dapsone.
DB00613
The risk or severity of adverse effects can be increased when Amodiaquine is combined with Dapsone.
DB00908
The risk or severity of adverse effects can be increased when Quinidine is combined with Dapsone.
DB01103
The risk or severity of adverse effects can be increased when Quinacrine is combined with Dapsone.
DB01117
The risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone.
DB01131
The risk or severity of adverse effects can be increased when Proguanil is combined with Dapsone.
DB01218
The risk or severity of adverse effects can be increased when Halofantrine is combined with Dapsone.
DB01299
The risk or severity of adverse effects can be increased when Sulfadoxine is combined with Dapsone.
DB01611
The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dapsone.
DB06608
The risk or severity of adverse effects can be increased when Tafenoquine is combined with Dapsone.
DB09274
The risk or severity of adverse effects can be increased when Artesunate is combined with Dapsone.
DB11638
The risk or severity of adverse effects can be increased when Artenimol is combined with Dapsone.
DB11809
The risk or severity of adverse effects can be increased when Artefenomel is combined with Dapsone.
DB12314
The risk or severity of adverse effects can be increased when Chlorproguanil is combined with Dapsone.
DB12617
The risk or severity of adverse effects can be increased when Mizoribine is combined with Dapsone.
DB12975
The risk or severity of adverse effects can be increased when Pyronaridine is combined with Dapsone.
DB13132
The risk or severity of adverse effects can be increased when Artemisinin is combined with Dapsone.
DB13851
The risk or severity of adverse effects can be increased when Artemotil is combined with Dapsone.
DB13941
The risk or severity of adverse effects can be increased when Piperaquine is combined with Dapsone.
DB14066
The risk or severity of adverse effects can be increased when Tetrandrine is combined with Dapsone.
DB14763
The risk or severity of adverse effects can be increased when Cycloguanil is combined with Dapsone.
DB00241
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Butalbital.
DB00252
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Phenytoin.
DB00281
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Lidocaine.
DB00316
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Acetaminophen.
DB00325
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitroprusside.
DB00359
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfadiazine.
DB00435
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitric Oxide.
DB00468
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Quinine.
DB00482
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Celecoxib.
DB00499
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Flutamide.
DB00608
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Chloroquine.
DB00698
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitrofurantoin.
DB00727
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitroglycerin.
DB00750
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Prilocaine.
DB00883
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Isosorbide dinitrate.
DB01015
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfamethoxazole.
DB01020
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Isosorbide mononitrate.
DB01086
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Benzocaine.
DB01087
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Primaquine.
DB01174
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Phenobarbital.
DB01198
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Zopiclone.
DB01233
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Metoclopramide.
DB01435
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Antipyrine.
DB01438
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Phenazopyridine.
DB01612
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Amyl Nitrite.
DB06706
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Isometheptene.
DB06795
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Mafenide.
DB06690
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitrous oxide.
DB00531
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Cyclophosphamide.
DB01181
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Ifosfamide.
DB00795
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfasalazine.
DB00259
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfanilamide.
DB00891
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Sulfapyridine.
DB00313
The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Valproic acid.
DB09096
The risk or severity of adverse effects can be increased when Benzoyl peroxide is combined with Dapsone.
DB00486
The metabolism of Dapsone can be decreased when combined with Nabilone.
DB00619
The metabolism of Dapsone can be decreased when combined with Imatinib.
DB00949
The metabolism of Dapsone can be decreased when combined with Felbamate.
DB01138
The metabolism of Dapsone can be decreased when combined with Sulfinpyrazone.
DB04818
The metabolism of Dapsone can be decreased when combined with Iproniazid.
DB05812
The metabolism of Dapsone can be decreased when combined with Abiraterone.
DB14009
The metabolism of Dapsone can be decreased when combined with Medical Cannabis.
DB00197
The metabolism of Dapsone can be decreased when combined with Troglitazone.
DB00176
The metabolism of Dapsone can be decreased when combined with Fluvoxamine.
DB00196
The metabolism of Dapsone can be decreased when combined with Fluconazole.
DB00322
The metabolism of Dapsone can be decreased when combined with Floxuridine.
DB00622
The metabolism of Dapsone can be decreased when combined with Nicardipine.
DB01110
The metabolism of Dapsone can be decreased when combined with Miconazole.
DB01241
The metabolism of Dapsone can be decreased when combined with Gemfibrozil.
DB06729
The metabolism of Dapsone can be decreased when combined with Sulfaphenazole.
DB00705
The metabolism of Dapsone can be decreased when combined with Delavirdine.
DB00418
The metabolism of Dapsone can be increased when combined with Secobarbital.
DB00307
The metabolism of Dapsone can be decreased when combined with Bexarotene.
DB00412
The metabolism of Dapsone can be decreased when combined with Rosiglitazone.
DB00421
The metabolism of Dapsone can be decreased when combined with Spironolactone.
DB00455
The metabolism of Dapsone can be decreased when combined with Loratadine.
DB00603
The metabolism of Dapsone can be decreased when combined with Medroxyprogesterone acetate.
DB01029
The metabolism of Dapsone can be decreased when combined with Irbesartan.
DB01062
The metabolism of Dapsone can be decreased when combined with Oxybutynin.
DB01095
The metabolism of Dapsone can be decreased when combined with Fluvastatin.
DB01129
The metabolism of Dapsone can be decreased when combined with Rabeprazole.
DB01132
The metabolism of Dapsone can be decreased when combined with Pioglitazone.
DB01645
The metabolism of Dapsone can be decreased when combined with Genistein.
DB01685
The metabolism of Dapsone can be decreased when combined with Topiroxostat.
DB06210
The metabolism of Dapsone can be decreased when combined with Eltrombopag.
DB08880
The metabolism of Dapsone can be decreased when combined with Teriflunomide.
DB09078
The metabolism of Dapsone can be decreased when combined with Lenvatinib.
DB00451
The metabolism of Dapsone can be decreased when combined with Levothyroxine.
DB00549
The metabolism of Dapsone can be decreased when combined with Zafirlukast.
DB00588
The metabolism of Dapsone can be decreased when combined with Fluticasone propionate.
DB00758
The metabolism of Dapsone can be decreased when combined with Clopidogrel.
DB00796
The metabolism of Dapsone can be decreased when combined with Candesartan cilexetil.
DB00938
The metabolism of Dapsone can be decreased when combined with Salmeterol.
DB08906
The metabolism of Dapsone can be decreased when combined with Fluticasone furoate.
DB08911
The metabolism of Dapsone can be decreased when combined with Trametinib.
DB13867
The metabolism of Dapsone can be decreased when combined with Fluticasone.
DB14512
The metabolism of Dapsone can be decreased when combined with Mometasone furoate.
DB01023
The metabolism of Felodipine can be decreased when combined with Dapsone.
DB12768
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dapsone.
DB14022
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dapsone.
DB08881
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dapsone.
DB11642
The serum concentration of Dapsone can be decreased when it is combined with Pitolisant.
DB09046
The metabolism of Dapsone can be increased when combined with Metreleptin.
DB00498
The risk or severity of bleeding can be increased when Dapsone is combined with Phenindione.
DB04665
The risk or severity of bleeding can be increased when Dapsone is combined with Coumarin.
DB08496
The risk or severity of bleeding can be increased when Dapsone is combined with (R)-warfarin.
DB13451
The risk or severity of bleeding can be increased when Dapsone is combined with Tioclomarol.
DB14055
The risk or severity of bleeding can be increased when Dapsone is combined with (S)-Warfarin.
DB03410
The risk or severity of bleeding can be increased when Dapsone is combined with 4-hydroxycoumarin.
DB08794
The risk or severity of bleeding can be increased when Dapsone is combined with Ethyl biscoumacetate.
DB13275
The risk or severity of bleeding can be increased when Dapsone is combined with Clorindione.
DB13347
The risk or severity of bleeding can be increased when Dapsone is combined with Diphenadione.
DB00220
The metabolism of Dapsone can be decreased when combined with Nelfinavir.
DB01026
The metabolism of Dapsone can be decreased when combined with Ketoconazole.
DB01167
The metabolism of Dapsone can be decreased when combined with Itraconazole.
DB01211
The metabolism of Dapsone can be decreased when combined with Clarithromycin.
DB08873
The metabolism of Dapsone can be decreased when combined with Boceprevir.
DB09065
The metabolism of Dapsone can be decreased when combined with Cobicistat.
DB13179
The metabolism of Dapsone can be decreased when combined with Troleandomycin.
DB01232
The metabolism of Dapsone can be decreased when combined with Saquinavir.
DB06448
The metabolism of Dapsone can be decreased when combined with Lonafarnib.
DB00501
The metabolism of Dapsone can be decreased when combined with Cimetidine.
DB00537
The metabolism of Dapsone can be decreased when combined with Ciprofloxacin.
DB00582
The metabolism of Dapsone can be decreased when combined with Voriconazole.
DB11633
The metabolism of Dapsone can be decreased when combined with Isavuconazole.
DB09061
The metabolism of Cannabidiol can be decreased when combined with Dapsone.
DB14011
The metabolism of Nabiximols can be decreased when combined with Dapsone.
DB00446
The metabolism of Dapsone can be decreased when combined with Chloramphenicol.
DB00673
The metabolism of Dapsone can be decreased when combined with Aprepitant.
DB00976
The metabolism of Dapsone can be decreased when combined with Telithromycin.
DB02520
The metabolism of Dapsone can be decreased when combined with Ditiocarb.
DB14635
The metabolism of Dapsone can be decreased when combined with Curcumin sulfate.
DB00845
The metabolism of Dapsone can be decreased when combined with Clofazimine.
DB15822
The metabolism of Dapsone can be decreased when combined with Pralsetinib.
DB11703
The metabolism of Dapsone can be decreased when combined with Acalabrutinib.
DB00224
The metabolism of Dapsone can be decreased when combined with Indinavir.
DB11837
The metabolism of Dapsone can be decreased when combined with Osilodrostat.
DB11737
The metabolism of Dapsone can be increased when combined with Icotinib.
DB00745
The metabolism of Dapsone can be increased when combined with Modafinil.
DB00625
The metabolism of Dapsone can be increased when combined with Efavirenz.
DB01222
The metabolism of Dapsone can be increased when combined with Budesonide.
DB01234
The metabolism of Dapsone can be increased when combined with Dexamethasone.
DB06413
The metabolism of Dapsone can be increased when combined with Armodafinil.
DB00206
The metabolism of Dapsone can be increased when combined with Reserpine.
DB00394
The metabolism of Dapsone can be increased when combined with Beclomethasone dipropionate.
DB00694
The metabolism of Dapsone can be increased when combined with Daunorubicin.
DB01041
The metabolism of Dapsone can be increased when combined with Thalidomide.
DB00776
The metabolism of Dapsone can be increased when combined with Oxcarbazepine.
DB00620
The metabolism of Dapsone can be increased when combined with Triamcinolone.
DB01380
The metabolism of Dapsone can be increased when combined with Cortisone acetate.
DB01384
The metabolism of Dapsone can be increased when combined with Paramethasone.
DB06595
The metabolism of Dapsone can be increased when combined with Midostaurin.
DB08970
The metabolism of Dapsone can be increased when combined with Fluprednidene.
DB09383
The metabolism of Dapsone can be increased when combined with Meprednisone.
DB11487
The metabolism of Dapsone can be increased when combined with Dexamethasone isonicotinate.
DB11921
The metabolism of Dapsone can be increased when combined with Deflazacort.
DB13003
The metabolism of Dapsone can be increased when combined with Cortivazol.
DB13208
The metabolism of Dapsone can be increased when combined with Prednylidene.
DB13843
The metabolism of Dapsone can be increased when combined with Cloprednol.
DB14631
The metabolism of Dapsone can be increased when combined with Prednisolone phosphate.
DB14633
The metabolism of Dapsone can be increased when combined with Prednisolone hemisuccinate.
DB14644
The metabolism of Dapsone can be increased when combined with Methylprednisolone hemisuccinate.
DB14646
The metabolism of Dapsone can be increased when combined with Prednisone acetate.
DB14652
The metabolism of Dapsone can be increased when combined with Clocortolone acetate.
DB14659
The metabolism of Dapsone can be increased when combined with Melengestrol acetate.
DB14669
The metabolism of Dapsone can be increased when combined with Betamethasone phosphate.
DB14681
The metabolism of Dapsone can be increased when combined with Cortisone.
DB01013
The metabolism of Dapsone can be increased when combined with Clobetasol propionate.
DB01047
The metabolism of Dapsone can be increased when combined with Fluocinonide.
DB00764
The metabolism of Dapsone can be increased when combined with Mometasone.
DB08971
The metabolism of Dapsone can be increased when combined with Fluocortolone.
DB11750
The metabolism of Dapsone can be increased when combined with Clobetasol.
DB09095
The metabolism of Dapsone can be increased when combined with Difluocortolone.
DB00738
The metabolism of Pentamidine can be decreased when combined with Dapsone.
DB01126
The metabolism of Dutasteride can be decreased when combined with Dapsone.
DB04957
The metabolism of Azimilide can be decreased when combined with Dapsone.
DB00203
The metabolism of Dapsone can be decreased when combined with Sildenafil.
DB00246
The metabolism of Dapsone can be decreased when combined with Ziprasidone.
DB00367
The metabolism of Levonorgestrel can be decreased when combined with Dapsone.
DB00401
The metabolism of Nisoldipine can be decreased when combined with Dapsone.
DB00404
The metabolism of Alprazolam can be decreased when combined with Dapsone.
DB00490
The metabolism of Buspirone can be decreased when combined with Dapsone.
DB00497
The metabolism of Oxycodone can be decreased when combined with Dapsone.
DB00514
The metabolism of Dextromethorphan can be decreased when combined with Dapsone.
DB00528
The metabolism of Lercanidipine can be decreased when combined with Dapsone.
DB00571
The metabolism of Propranolol can be decreased when combined with Dapsone.
DB00624
The metabolism of Testosterone can be decreased when combined with Dapsone.
DB00656
The metabolism of Trazodone can be decreased when combined with Dapsone.
DB00683
The metabolism of Midazolam can be decreased when combined with Dapsone.
DB00700
The metabolism of Eplerenone can be decreased when combined with Dapsone.
DB00701
The metabolism of Amprenavir can be decreased when combined with Dapsone.
DB00717
The metabolism of Norethisterone can be decreased when combined with Dapsone.
DB00731
The metabolism of Nateglinide can be decreased when combined with Dapsone.
DB00734
The metabolism of Risperidone can be decreased when combined with Dapsone.
DB00762
The metabolism of Irinotecan can be decreased when combined with Dapsone.
DB00820
The metabolism of Tadalafil can be decreased when combined with Dapsone.
DB00822
The metabolism of Disulfiram can be decreased when combined with Dapsone.
DB00829
The metabolism of Diazepam can be decreased when combined with Dapsone.
DB00862
The metabolism of Vardenafil can be decreased when combined with Dapsone.
DB00897
The metabolism of Triazolam can be decreased when combined with Dapsone.
DB00904
The metabolism of Ondansetron can be decreased when combined with Dapsone.
DB00909
The metabolism of Zonisamide can be decreased when combined with Dapsone.
DB00962
The metabolism of Zaleplon can be decreased when combined with Dapsone.
DB01054
The metabolism of Nitrendipine can be decreased when combined with Dapsone.
DB01058
The metabolism of Praziquantel can be decreased when combined with Dapsone.
DB01114
The metabolism of Chlorpheniramine can be decreased when combined with Dapsone.
DB01166
The metabolism of Cilostazol can be decreased when combined with Dapsone.
DB01216
The metabolism of Finasteride can be decreased when combined with Dapsone.
DB01224
The metabolism of Quetiapine can be decreased when combined with Dapsone.
DB01238
The metabolism of Aripiprazole can be decreased when combined with Dapsone.
DB01267
The metabolism of Paliperidone can be decreased when combined with Dapsone.
DB04946
The metabolism of Iloperidone can be decreased when combined with Dapsone.
DB05521
The metabolism of Telaprevir can be decreased when combined with Dapsone.
DB06176
The metabolism of Romidepsin can be decreased when combined with Dapsone.
DB06228
The metabolism of Rivaroxaban can be decreased when combined with Dapsone.
DB06267
The metabolism of Udenafil can be decreased when combined with Dapsone.
DB06335
The metabolism of Saxagliptin can be decreased when combined with Dapsone.
DB06403
The metabolism of Ambrisentan can be decreased when combined with Dapsone.
DB06419
The metabolism of Cethromycin can be decreased when combined with Dapsone.
DB06652
The metabolism of Vicriviroc can be decreased when combined with Dapsone.
DB06789
The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Dapsone.
DB08820
The metabolism of Ivacaftor can be decreased when combined with Dapsone.
DB08883
The metabolism of Perampanel can be decreased when combined with Dapsone.
DB09053
The metabolism of Ibrutinib can be decreased when combined with Dapsone.
DB09102
The metabolism of Daclatasvir can be decreased when combined with Dapsone.
DB09231
The metabolism of Benidipine can be decreased when combined with Dapsone.
DB09297
The metabolism of Paritaprevir can be decreased when combined with Dapsone.
DB11586
The metabolism of Asunaprevir can be decreased when combined with Dapsone.
DB11712
The metabolism of Tezacaftor can be decreased when combined with Dapsone.
DB11915
The metabolism of Valbenazine can be decreased when combined with Dapsone.
DB12161
The metabolism of Deutetrabenazine can be decreased when combined with Dapsone.
DB12301
The metabolism of Doravirine can be decreased when combined with Dapsone.
DB14185
The metabolism of Aripiprazole lauroxil can be decreased when combined with Dapsone.
DB14541
The metabolism of Hydrocortisone cypionate can be decreased when combined with Dapsone.
DB15444
The metabolism of Elexacaftor can be decreased when combined with Dapsone.
DB01098
The metabolism of Rosuvastatin can be decreased when combined with Dapsone.
DB09237
The metabolism of Levamlodipine can be decreased when combined with Dapsone.
DB11951
The metabolism of Lemborexant can be decreased when combined with Dapsone.
DB00557
The metabolism of Hydroxyzine can be decreased when combined with Dapsone.
DB01190
The metabolism of Clindamycin can be decreased when combined with Dapsone.
DB00802
The metabolism of Alfentanil can be decreased when combined with Dapsone.
DB00813
The metabolism of Fentanyl can be decreased when combined with Dapsone.
DB00655
The metabolism of Estrone can be decreased when combined with Dapsone.
DB00091
The metabolism of Cyclosporine can be decreased when combined with Dapsone.
DB00564
The metabolism of Carbamazepine can be decreased when combined with Dapsone.
DB00864
The metabolism of Tacrolimus can be decreased when combined with Dapsone.
DB00877
The metabolism of Sirolimus can be decreased when combined with Dapsone.
DB01100
The metabolism of Pimozide can be decreased when combined with Dapsone.
DB01229
The metabolism of Paclitaxel can be decreased when combined with Dapsone.
DB06287
The metabolism of Temsirolimus can be decreased when combined with Dapsone.
DB08901
The metabolism of Dapsone can be decreased when combined with Ponatinib.
DB06772
The metabolism of Cabazitaxel can be decreased when combined with Dapsone.
DB00444
The metabolism of Dapsone can be decreased when combined with Teniposide.
DB04855
The metabolism of Dapsone can be decreased when combined with Dronedarone.
DB08865
The metabolism of Dapsone can be decreased when combined with Crizotinib.
DB00541
The metabolism of Vincristine can be decreased when combined with Dapsone.
DB00637
The metabolism of Astemizole can be decreased when combined with Dapsone.
DB00773
The metabolism of Etoposide can be decreased when combined with Dapsone.
DB01248
The metabolism of Docetaxel can be decreased when combined with Dapsone.
DB01254
The metabolism of Dasatinib can be decreased when combined with Dapsone.
DB01268
The metabolism of Sunitinib can be decreased when combined with Dapsone.
DB05773
The metabolism of Trastuzumab emtansine can be decreased when combined with Dapsone.
DB06626
The metabolism of Axitinib can be decreased when combined with Dapsone.
DB09074
The metabolism of Olaparib can be decreased when combined with Dapsone.
DB12483
The metabolism of Copanlisib can be decreased when combined with Dapsone.
DB00575
The metabolism of Clonidine can be decreased when combined with Dapsone.
DB01079
The metabolism of Dapsone can be decreased when combined with Tegaserod.
DB01009
The metabolism of Dapsone can be decreased when combined with Ketoprofen.
DB12245
The metabolism of Dapsone can be decreased when combined with Triclabendazole.
DB00255
The metabolism of Dapsone can be decreased when combined with Diethylstilbestrol.
DB00439
The metabolism of Dapsone can be decreased when combined with Cerivastatin.
DB00471
The metabolism of Dapsone can be decreased when combined with Montelukast.
DB00481
The metabolism of Dapsone can be decreased when combined with Raloxifene.
DB00554
The metabolism of Dapsone can be decreased when combined with Piroxicam.
DB00661
The metabolism of Dapsone can be decreased when combined with Verapamil.
DB00665
The metabolism of Dapsone can be decreased when combined with Nilutamide.
DB00780
The metabolism of Dapsone can be decreased when combined with Phenelzine.
DB00916
The metabolism of Dapsone can be decreased when combined with Metronidazole.
DB00977
The metabolism of Dapsone can be decreased when combined with Ethinylestradiol.
DB01259
The metabolism of Dapsone can be decreased when combined with Lapatinib.
DB01393
The metabolism of Dapsone can be decreased when combined with Bezafibrate.
DB01583
The metabolism of Dapsone can be decreased when combined with Liotrix.
DB01609
The metabolism of Dapsone can be decreased when combined with Deferasirox.
DB01698
The metabolism of Dapsone can be decreased when combined with Rutin.
DB04216
The metabolism of Dapsone can be decreased when combined with Quercetin.
DB04725
The metabolism of Dapsone can be decreased when combined with Licofelone.
DB06616
The metabolism of Dapsone can be decreased when combined with Bosutinib.
DB06712
The metabolism of Dapsone can be decreased when combined with Nilvadipine.
DB08828
The metabolism of Dapsone can be decreased when combined with Vismodegib.
DB08896
The metabolism of Dapsone can be decreased when combined with Regorafenib.
DB11632
The metabolism of Dapsone can be decreased when combined with Opicapone.
DB12070
The metabolism of Dapsone can be decreased when combined with Letermovir.
DB13919
The metabolism of Dapsone can be decreased when combined with Candesartan.
DB00784
The metabolism of Dapsone can be decreased when combined with Mefenamic acid.
DB00342
The metabolism of Terfenadine can be decreased when combined with Dapsone.
DB00641
The metabolism of Simvastatin can be decreased when combined with Dapsone.
DB01115
The metabolism of Nifedipine can be decreased when combined with Dapsone.
DB00678
The metabolism of Dapsone can be decreased when combined with Losartan.
DB01394
The metabolism of Dapsone can be decreased when combined with Colchicine.
DB09280
The metabolism of Dapsone can be decreased when combined with Lumacaftor.
DB11753
The metabolism of Dapsone can be decreased when combined with Rifamycin.
DB12466
The metabolism of Dapsone can be decreased when combined with Favipiravir.
DB11995
The metabolism of Dapsone can be increased when combined with Avatrombopag.
DB00615
The metabolism of Dapsone can be increased when combined with Rifabutin.
DB01201
The metabolism of Dapsone can be increased when combined with Rifapentine.
DB00400
The metabolism of Dapsone can be increased when combined with Griseofulvin.
DB00741
The metabolism of Dapsone can be increased when combined with Hydrocortisone.
DB14539
The metabolism of Dapsone can be increased when combined with Hydrocortisone acetate.
DB14545
The metabolism of Dapsone can be increased when combined with Hydrocortisone succinate.
DB01220
The metabolism of Dapsone can be increased when combined with Rifaximin.
DB00443
The metabolism of Dapsone can be increased when combined with Betamethasone.
DB14540
The metabolism of Hydrocortisone butyrate can be increased when combined with Dapsone.
DB14542
The metabolism of Hydrocortisone phosphate can be increased when combined with Dapsone.
DB00347
The metabolism of Trimethadione can be decreased when combined with Dapsone.
DB06605
The metabolism of Apixaban can be decreased when combined with Dapsone.
DB09068
The metabolism of Vortioxetine can be decreased when combined with Dapsone.
DB00921
The metabolism of Dapsone can be decreased when combined with Buprenorphine.
DB00972
The metabolism of Dapsone can be decreased when combined with Azelastine.
DB01424
The metabolism of Dapsone can be decreased when combined with Aminophenazone.
DB09198
The metabolism of Dapsone can be decreased when combined with Lobeglitazone.
DB00184
The metabolism of Dapsone can be decreased when combined with Nicotine.
DB00214
The metabolism of Dapsone can be decreased when combined with Torasemide.
DB00295
The metabolism of Morphine can be decreased when combined with Dapsone.
DB00402
The metabolism of Eszopiclone can be decreased when combined with Dapsone.
DB00495
The metabolism of Zidovudine can be decreased when combined with Dapsone.
DB00586
The metabolism of Diclofenac can be decreased when combined with Dapsone.
DB00617
The metabolism of Paramethadione can be decreased when combined with Dapsone.
DB00688
The metabolism of Mycophenolate mofetil can be decreased when combined with Dapsone.
DB00755
The metabolism of Tretinoin can be decreased when combined with Dapsone.
DB00788
The metabolism of Naproxen can be decreased when combined with Dapsone.
DB00799
The metabolism of Tazarotene can be decreased when combined with Dapsone.
DB00818
The metabolism of Propofol can be decreased when combined with Dapsone.
DB00912
The metabolism of Repaglinide can be decreased when combined with Dapsone.
DB00918
The metabolism of Almotriptan can be decreased when combined with Dapsone.
DB01037
The metabolism of Selegiline can be decreased when combined with Dapsone.
DB01050
The metabolism of Ibuprofen can be decreased when combined with Dapsone.
DB01124
The metabolism of Tolbutamide can be decreased when combined with Dapsone.
DB01184
The metabolism of Domperidone can be decreased when combined with Dapsone.
DB01261
The metabolism of Sitagliptin can be decreased when combined with Dapsone.
DB01357
The metabolism of Mestranol can be decreased when combined with Dapsone.
DB05229
The metabolism of Beraprost can be decreased when combined with Dapsone.
DB06510
The metabolism of Muraglitazar can be decreased when combined with Dapsone.
DB06670
The metabolism of Odanacatib can be decreased when combined with Dapsone.
DB06738
The metabolism of Ketobemidone can be decreased when combined with Dapsone.
DB06770
The metabolism of Benzyl alcohol can be decreased when combined with Dapsone.
DB08860
The metabolism of Pitavastatin can be decreased when combined with Dapsone.
DB08918
The metabolism of Levomilnacipran can be decreased when combined with Dapsone.
DB08922
The metabolism of Perospirone can be decreased when combined with Dapsone.
DB08931
The metabolism of Riociguat can be decreased when combined with Dapsone.
DB09080
The metabolism of Olodaterol can be decreased when combined with Dapsone.
DB09183
The metabolism of Dasabuvir can be decreased when combined with Dapsone.
DB09199
The metabolism of Netoglitazone can be decreased when combined with Dapsone.
DB09200
The metabolism of Rivoglitazone can be decreased when combined with Dapsone.
DB09201
The metabolism of Ciglitazone can be decreased when combined with Dapsone.
DB09296
The metabolism of Ombitasvir can be decreased when combined with Dapsone.
DB11362
The metabolism of Selexipag can be decreased when combined with Dapsone.
DB11613
The metabolism of Velpatasvir can be decreased when combined with Dapsone.
DB11978
The metabolism of Glasdegib can be decreased when combined with Dapsone.
DB11979
The metabolism of Elagolix can be decreased when combined with Dapsone.
DB12026
The metabolism of Voxilaprevir can be decreased when combined with Dapsone.
DB12781
The metabolism of Balaglitazone can be decreased when combined with Dapsone.
DB01217
The metabolism of Dapsone can be decreased when combined with Anastrozole.
DB01076
The metabolism of Atorvastatin can be decreased when combined with Dapsone.
DB00532
The metabolism of Mephenytoin can be decreased when combined with Dapsone.
DB12130
The metabolism of Lorlatinib can be decreased when combined with Dapsone.
DB11757
The metabolism of Istradefylline can be decreased when combined with Dapsone.
DB09213
The metabolism of Dexibuprofen can be decreased when combined with Dapsone.
DB09288
The metabolism of Propacetamol can be decreased when combined with Dapsone.
DB08502
The metabolism of Capravirine can be decreased when combined with Dapsone.
DB00465
The metabolism of Ketorolac can be decreased when combined with Dapsone.
DB00333
The metabolism of Methadone can be decreased when combined with Dapsone.
DB00783
The metabolism of Estradiol can be decreased when combined with Dapsone.
DB13943
The metabolism of Testosterone cypionate can be decreased when combined with Dapsone.
DB13944
The metabolism of Testosterone enanthate can be decreased when combined with Dapsone.
DB13946
The metabolism of Testosterone undecanoate can be decreased when combined with Dapsone.
DB13952
The metabolism of Estradiol acetate can be decreased when combined with Dapsone.
DB13953
The metabolism of Estradiol benzoate can be decreased when combined with Dapsone.
DB13954
The metabolism of Estradiol cypionate can be decreased when combined with Dapsone.
DB13955
The metabolism of Estradiol dienanthate can be decreased when combined with Dapsone.
DB13956
The metabolism of Estradiol valerate can be decreased when combined with Dapsone.
DB11901
The metabolism of Dapsone can be decreased when combined with Apalutamide.
DB00338
The metabolism of Omeprazole can be decreased when combined with Dapsone.
DB00857
The metabolism of Terbinafine can be decreased when combined with Dapsone.
DB01221
The metabolism of Ketamine can be decreased when combined with Dapsone.
DB06739
The metabolism of Seratrodast can be decreased when combined with Dapsone.
DB00277
The metabolism of Theophylline can be decreased when combined with Dapsone.
DB00836
The metabolism of Loperamide can be decreased when combined with Dapsone.
DB00321
The metabolism of Amitriptyline can be decreased when combined with Dapsone.
DB12612
The metabolism of Ozanimod can be decreased when combined with Dapsone.
DB11689
The metabolism of Selumetinib can be decreased when combined with Dapsone.
DB00714
The metabolism of Apomorphine can be decreased when combined with Dapsone.
DB00398
The metabolism of Dapsone can be decreased when combined with Sorafenib.
DB00530
The metabolism of Dapsone can be decreased when combined with Erlotinib.
DB13874
The metabolism of Dapsone can be decreased when combined with Enasidenib.
DB00544
The metabolism of Fluorouracil can be decreased when combined with Dapsone.
DB06589
The metabolism of Pazopanib can be decreased when combined with Dapsone.
DB09256
The metabolism of Tegafur can be decreased when combined with Dapsone.
DB12267
The metabolism of Brigatinib can be decreased when combined with Dapsone.
DB01118
The metabolism of Amiodarone can be decreased when combined with Dapsone.
DB08912
The metabolism of Dapsone can be decreased when combined with Dabrafenib.
DB00343
The metabolism of Dapsone can be decreased when combined with Diltiazem.
DB06730
The metabolism of Dapsone can be decreased when combined with Gestodene.
DB00199
The metabolism of Dapsone can be decreased when combined with Erythromycin.
DB01059
The metabolism of Dapsone can be decreased when combined with Norfloxacin.
DB01388
The metabolism of Dapsone can be decreased when combined with Mibefradil.
DB06412
The metabolism of Dapsone can be decreased when combined with Oxymetholone.
DB11574
The metabolism of Dapsone can be decreased when combined with Elbasvir.
DB01045
The metabolism of Dapsone can be increased when combined with Rifampicin.
DB05804
The metabolism of Prasterone sulfate can be decreased when combined with Dapsone.
DB00458
The metabolism of Imipramine can be decreased when combined with Dapsone.
DB01227
The metabolism of Levacetylmethadol can be decreased when combined with Dapsone.
DB08899
The metabolism of Enzalutamide can be increased when combined with Dapsone.
DB00559
The metabolism of Dapsone can be increased when combined with Bosentan.
DB00022
The metabolism of Dapsone can be increased when combined with Peginterferon alfa-2b.
DB11943
The metabolism of Dapsone can be increased when combined with Delafloxacin.
DB09238
The metabolism of Dapsone can be decreased when combined with Manidipine.
DB01128
The metabolism of Dapsone can be decreased when combined with Bicalutamide.
DB00177
The metabolism of Dapsone can be decreased when combined with Valsartan.
DB00263
The metabolism of Dapsone can be decreased when combined with Sulfisoxazole.
DB00323
The metabolism of Dapsone can be decreased when combined with Tolcapone.
DB00515
The metabolism of Dapsone can be decreased when combined with Cisplatin.
DB00576
The metabolism of Dapsone can be decreased when combined with Sulfamethizole.
DB00621
The metabolism of Dapsone can be decreased when combined with Oxandrolone.
DB00668
The metabolism of Dapsone can be decreased when combined with Epinephrine.
DB00715
The metabolism of Dapsone can be decreased when combined with Paroxetine.
DB01016
The metabolism of Dapsone can be decreased when combined with Glyburide.
DB01039
The metabolism of Dapsone can be decreased when combined with Fenofibrate.
DB01097
The metabolism of Dapsone can be decreased when combined with Leflunomide.
DB01104
The metabolism of Dapsone can be decreased when combined with Sertraline.
DB01176
The metabolism of Dapsone can be decreased when combined with Cyclizine.
DB01195
The metabolism of Dapsone can be decreased when combined with Flecainide.
DB01381
The metabolism of Dapsone can be decreased when combined with Ginkgo biloba.
DB01411
The metabolism of Dapsone can be decreased when combined with Pranlukast.
DB03756
The metabolism of Dapsone can be decreased when combined with Doconexent.
DB04574
The metabolism of Dapsone can be decreased when combined with Estrone sulfate.
DB06150
The metabolism of Dapsone can be decreased when combined with Sulfadimethoxine.
DB06174
The metabolism of Dapsone can be decreased when combined with Noscapine.
DB06442
The metabolism of Dapsone can be decreased when combined with Avasimibe.
DB06594
The metabolism of Dapsone can be decreased when combined with Agomelatine.
DB06654
The metabolism of Dapsone can be decreased when combined with Safinamide.
DB06731
The metabolism of Dapsone can be decreased when combined with Seproxetine.
DB08798
The metabolism of Dapsone can be decreased when combined with Sulfamoxole.
DB09063
The metabolism of Dapsone can be decreased when combined with Ceritinib.
DB11994
The metabolism of Dapsone can be decreased when combined with Diacerein.
DB12332
The metabolism of Dapsone can be decreased when combined with Rucaparib.
DB13975
The metabolism of Dapsone can be decreased when combined with Black cohosh.
DB09167
The metabolism of Dapsone can be decreased when combined with Dosulepin.
DB12319
The metabolism of Dapsone can be decreased when combined with Benzbromarone.
DB04856
The metabolism of Dexloxiglumide can be decreased when combined with Dapsone.
DB04831
The metabolism of Dapsone can be decreased when combined with Tienilic acid.
DB00227
The metabolism of Dapsone can be decreased when combined with Lovastatin.
DB00238
The metabolism of Dapsone can be decreased when combined with Nevirapine.
DB00317
The metabolism of Gefitinib can be decreased when combined with Dapsone.
DB00396
The metabolism of Progesterone can be decreased when combined with Dapsone.
DB00472
The metabolism of Fluoxetine can be decreased when combined with Dapsone.
DB00604
The metabolism of Cisapride can be decreased when combined with Dapsone.
DB00448
The metabolism of Dapsone can be decreased when combined with Lansoprazole.
DB00752
The metabolism of Dapsone can be decreased when combined with Tranylcypromine.
DB00763
The metabolism of Dapsone can be decreased when combined with Methimazole.
DB00812
The metabolism of Dapsone can be decreased when combined with Phenylbutazone.
DB00898
The metabolism of Dapsone can be decreased when combined with Ethanol.
DB00951
The metabolism of Dapsone can be decreased when combined with Isoniazid.
DB01628
The metabolism of Dapsone can be decreased when combined with Etoricoxib.
DB04868
The metabolism of Dapsone can be decreased when combined with Nilotinib.
DB04920
The metabolism of Dapsone can be decreased when combined with Clevidipine.
DB06268
The metabolism of Dapsone can be decreased when combined with Sitaxentan.
DB06414
The metabolism of Dapsone can be decreased when combined with Etravirine.
DB09118
The metabolism of Dapsone can be decreased when combined with Stiripentol.
DB01072
The metabolism of Atazanavir can be decreased when combined with Dapsone.
DB13174
The metabolism of Dapsone can be decreased when combined with Rhein.
DB14033
The metabolism of Dapsone can be decreased when combined with Acetyl sulfisoxazole.
DB00334
The metabolism of Dapsone can be decreased when combined with Olanzapine.
DB00208
The metabolism of Dapsone can be decreased when combined with Ticlopidine.
DB00580
The metabolism of Dapsone can be decreased when combined with Valdecoxib.
DB04911
The metabolism of Dapsone can be decreased when combined with Oritavancin.
DB08816
The metabolism of Dapsone can be decreased when combined with Ticagrelor.
DB00222
The metabolism of Dapsone can be decreased when combined with Glimepiride.
DB00374
The metabolism of Treprostinil can be decreased when combined with Dapsone.
DB00414
The metabolism of Acetohexamide can be decreased when combined with Dapsone.
DB00461
The metabolism of Nabumetone can be decreased when combined with Dapsone.
DB00469
The metabolism of Tenoxicam can be decreased when combined with Dapsone.
DB00672
The metabolism of Chlorpropamide can be decreased when combined with Dapsone.
DB00712
The metabolism of Flurbiprofen can be decreased when combined with Dapsone.
DB00749
The metabolism of Etodolac can be decreased when combined with Dapsone.
DB00839
The metabolism of Tolazamide can be decreased when combined with Dapsone.
DB00936
The metabolism of Salicylic acid can be decreased when combined with Dapsone.
DB00945
The metabolism of Acetylsalicylic acid can be decreased when combined with Dapsone.
DB00983
The metabolism of Formoterol can be decreased when combined with Dapsone.
DB01065
The metabolism of Melatonin can be decreased when combined with Dapsone.
DB01075
The metabolism of Diphenhydramine can be decreased when combined with Dapsone.
DB01177
The metabolism of Idarubicin can be decreased when combined with Dapsone.
DB01251
The metabolism of Gliquidone can be decreased when combined with Dapsone.
DB01274
The metabolism of Arformoterol can be decreased when combined with Dapsone.
DB01283
The metabolism of Lumiracoxib can be decreased when combined with Dapsone.
DB01289
The metabolism of Glisoxepide can be decreased when combined with Dapsone.
DB04557
The metabolism of Arachidonic Acid can be decreased when combined with Dapsone.
DB04898
The metabolism of Ximelagatran can be decreased when combined with Dapsone.
DB06204
The metabolism of Tapentadol can be decreased when combined with Dapsone.
DB06209
The metabolism of Prasugrel can be decreased when combined with Dapsone.
DB06725
The metabolism of Lornoxicam can be decreased when combined with Dapsone.
DB06737
The metabolism of Zaltoprofen can be decreased when combined with Dapsone.
DB06803
The metabolism of Niclosamide can be decreased when combined with Dapsone.
DB08962
The metabolism of Glibornuride can be decreased when combined with Dapsone.
DB11560
The metabolism of Lesinurad can be decreased when combined with Dapsone.
DB13406
The metabolism of Carbutamide can be decreased when combined with Dapsone.
DB13675
The metabolism of Metahexamide can be decreased when combined with Dapsone.
DB00327
The metabolism of Hydromorphone can be decreased when combined with Dapsone.
DB00328
The metabolism of Indomethacin can be decreased when combined with Dapsone.
DB01067
The metabolism of Glipizide can be decreased when combined with Dapsone.
DB01120
The metabolism of Gliclazide can be decreased when combined with Dapsone.
DB01171
The metabolism of Moclobemide can be decreased when combined with Dapsone.
DB01355
The metabolism of Hexobarbital can be decreased when combined with Dapsone.
DB00216
The metabolism of Dapsone can be decreased when combined with Eletriptan.
DB00285
The metabolism of Venlafaxine can be decreased when combined with Dapsone.
DB00304
The metabolism of Desogestrel can be decreased when combined with Dapsone.
DB00363
The metabolism of Clozapine can be decreased when combined with Dapsone.
DB00425
The metabolism of Zolpidem can be decreased when combined with Dapsone.
DB00470
The metabolism of Dronabinol can be decreased when combined with Dapsone.
DB00476
The metabolism of Duloxetine can be decreased when combined with Dapsone.
DB00533
The metabolism of Rofecoxib can be decreased when combined with Dapsone.
DB00568
The metabolism of Cinnarizine can be decreased when combined with Dapsone.
DB00590
The metabolism of Doxazosin can be decreased when combined with Dapsone.
DB00744
The metabolism of Zileuton can be decreased when combined with Dapsone.
DB00794
The metabolism of Primidone can be decreased when combined with Dapsone.
DB00843
The metabolism of Donepezil can be decreased when combined with Dapsone.
DB00969
The metabolism of Alosetron can be decreased when combined with Dapsone.
DB00980
The metabolism of Ramelteon can be decreased when combined with Dapsone.
DB01028
The metabolism of Methoxyflurane can be decreased when combined with Dapsone.
DB01036
The metabolism of Tolterodine can be decreased when combined with Dapsone.
DB01136
The metabolism of Carvedilol can be decreased when combined with Dapsone.
DB01154
The metabolism of Thiamylal can be decreased when combined with Dapsone.
DB01159
The metabolism of Halothane can be decreased when combined with Dapsone.
DB01544
The metabolism of Flunitrazepam can be decreased when combined with Dapsone.
DB01589
The metabolism of Quazepam can be decreased when combined with Dapsone.
DB03783
The metabolism of Phenacetin can be decreased when combined with Dapsone.
DB04841
The metabolism of Flunarizine can be decreased when combined with Dapsone.
DB04938
The metabolism of Ospemifene can be decreased when combined with Dapsone.
DB05541
The metabolism of Brivaracetam can be decreased when combined with Dapsone.
DB06218
The metabolism of Lacosamide can be decreased when combined with Dapsone.
DB06292
The metabolism of Dapagliflozin can be decreased when combined with Dapsone.
DB06370
The metabolism of Indisulam can be decreased when combined with Dapsone.
DB07615
The metabolism of Tranilast can be decreased when combined with Dapsone.
DB09048
The metabolism of Netupitant can be decreased when combined with Dapsone.
DB11614
The metabolism of Rupatadine can be decreased when combined with Dapsone.
DB11823
The metabolism of Esketamine can be decreased when combined with Dapsone.
DB12474
The metabolism of Lynestrenol can be decreased when combined with Dapsone.
DB14975
The metabolism of Voxelotor can be decreased when combined with Dapsone.
DB01156
The metabolism of Bupropion can be decreased when combined with Dapsone.
DB08439
The metabolism of Parecoxib can be decreased when combined with Dapsone.
DB15233
The metabolism of Avapritinib can be decreased when combined with Dapsone.
DB00814
The metabolism of Meloxicam can be decreased when combined with Dapsone.
DB01142
The metabolism of Doxepin can be decreased when combined with Dapsone.
DB00188
The metabolism of Dapsone can be decreased when combined with Bortezomib.
DB00957
The metabolism of Norgestimate can be decreased when combined with Dapsone.
DB01101
The metabolism of Dapsone can be decreased when combined with Capecitabine.
DB00675
The metabolism of Dapsone can be decreased when combined with Tamoxifen.
DB00266
The metabolism of Dicoumarol can be decreased when combined with Dapsone.
DB00726
The metabolism of Trimipramine can be decreased when combined with Dapsone.
DB00682
The metabolism of Dapsone can be decreased when combined with Warfarin.
DB01320
The metabolism of Fosphenytoin can be decreased when combined with Dapsone.
DB05109
The metabolism of Trabectedin can be decreased when combined with Dapsone.
DB08875
The metabolism of Cabozantinib can be decreased when combined with Dapsone.
DB11963
The metabolism of Dacomitinib can be decreased when combined with Dapsone.
DB12147
The metabolism of Erdafitinib can be decreased when combined with Dapsone.
DB12371
The metabolism of Siponimod can be decreased when combined with Dapsone.
DB00946
The metabolism of Phenprocoumon can be increased when combined with Dapsone.
DB01418
The metabolism of Acenocoumarol can be increased when combined with Dapsone.
DB13136
The metabolism of Fluindione can be increased when combined with Dapsone.
DB06273
The metabolism of Dapsone can be increased when combined with Tocilizumab.
DB00005
The metabolism of Dapsone can be increased when combined with Etanercept.
DB00026
The metabolism of Dapsone can be increased when combined with Anakinra.
DB00051
The metabolism of Dapsone can be increased when combined with Adalimumab.
DB00065
The metabolism of Dapsone can be increased when combined with Infliximab.
DB01281
The metabolism of Dapsone can be increased when combined with Abatacept.
DB04956
The metabolism of Dapsone can be increased when combined with Afelimomab.
DB05676
The metabolism of Dapsone can be increased when combined with Apremilast.
DB06168
The metabolism of Dapsone can be increased when combined with Canakinumab.
DB06372
The metabolism of Dapsone can be increased when combined with Rilonacept.
DB06674
The metabolism of Dapsone can be increased when combined with Golimumab.
DB08904
The metabolism of Dapsone can be increased when combined with Certolizumab pegol.
DB09029
The metabolism of Dapsone can be increased when combined with Secukinumab.
DB09036
The metabolism of Dapsone can be increased when combined with Siltuximab.
DB14724
The metabolism of Dapsone can be increased when combined with Emapalumab.
DB00649
The risk or severity of peripheral neuropathy can be increased when Stavudine is combined with Dapsone.
DB00581
The therapeutic efficacy of Lactulose can be decreased when used in combination with Dapsone.
DB12015
The serum concentration of Dapsone can be decreased when it is combined with Alpelisib.
DB06119
The serum concentration of Dapsone can be decreased when it is combined with Cenobamate.
DB00503
The serum concentration of Dapsone can be increased when it is combined with Ritonavir.
DB00502
The serum concentration of Haloperidol can be increased when it is combined with Dapsone.
DB14443
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dapsone.
DB11652
The metabolism of Tucatinib can be decreased when combined with Dapsone.
DB15685
The serum concentration of Dapsone can be increased when it is combined with Selpercatinib.
DB00819
The therapeutic efficacy of Dapsone can be increased when used in combination with Acetazolamide.
DB11932
The serum concentration of Dapsone can be increased when it is combined with Abametapir.
DB15762
The serum concentration of Dapsone can be decreased when it is combined with Satralizumab.

序列

实验性质

Water Solubility
380 mg/L (at 37 °C)
YALKOWSKY,SH & DANNENFELSER,RM (1992)
Melting Point
175.5 °C

logP
0.97
HANSCH,C ET AL. (1995)
logS
-2.82
ADME Research, USCD
pKa
2.41
PERRIN,DD (1965)

外部标识符

resource：Drugs Product Database (DPD)
identifier：8120
resource：ChEBI
identifier：4325
resource：PubChem Compound
identifier：2955
resource：PubChem Substance
identifier：46505300
resource：KEGG Compound
identifier：C07666
resource：KEGG Drug
identifier：D00592
resource：ChemSpider
identifier：2849
resource：BindingDB
identifier：50029764
resource：PharmGKB
identifier：PA449211
resource：Therapeutic Targets Database
identifier：DAP000637
resource：Wikipedia
identifier：Dapsone
resource：ChEMBL
identifier：CHEMBL1043
resource：ZINC
identifier：ZINC000000006310
resource：RxCUI
identifier：3108

外部链接

RxList
http://www.rxlist.com/cgi/generic/dapsone.htm
Drugs.com
http://www.drugs.com/cdi/dapsone.html

路径

目标

id:BE0002087
name:Inactive dihydropteroate synthase 2
organism:Mycobacterium leprae (strain TN)
action:inhibitor
Gillis TP, Williams DL: Dapsone resistance does not appear to be associated with a mutation in the dihydropteroate synthase-2 gene of Mycobacterium leprae. Indian J Lepr. 1999 Jan-Mar;71(1):11-8.
Williams DL, Spring L, Harris E, Roche P, Gillis TP: Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother. 2000 Jun;44(6):1530-7.
Gengenbacher M, Xu T, Niyomrattanakit P, Spraggon G, Dick T: Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett. 2008 Oct;287(1):128-35. doi: 10.1111/j.1574-6968.2008.01302.x. Epub 2008 Aug 1.
known-action:yes
name:Inactive dihydropteroate synthase 2
general-function:Has very low affinity for the DHPS substrate 6-hydroxymethyl-7,8-dihydropterin-pyrophosphate, but can bind the inhibitor dapsone. Seems to lack dihydropteroate synthase activity, and does probably not function in folate metabolism (By similarity).
specific-function:Dihydropteroate synthase activity
gene-name:folP2
locus:
cellular-location:
transmembrane-regions:
signal-regions:
theoretical-pi:6.4
molecular-weight:30850.89
chromosome-location:
organism:Mycobacterium leprae (strain TN)
external-identifiers:GenBank Gene DatabaseU15180GenBank Protein Database699152UniProtKBP0C0X2UniProt AccessionDHPS2_MYCLE
synonyms:DHPS 2Dihydropteroate pyrophosphorylase 2
amino-acid-sequence:>lcl|BSEQ0011514|Inactive dihydropteroate synthase 2 MQSMLCGRPVAADRQLIMAIVNRTPDSFYDRGATFSDEAARAAAHRAVAEGADVIDVGGV KAGPGQGVDVDTEIARLVPFIEWLRSAYTDLLISVDTWRAEVARLACTAGADLINDSWGG ADPAMHEVAAELGAGLVCSHTGGALPRTRPFRVSYGTTTRGVVDDVIRQVTAAAERAVAA GVTRDSVLVDPTHDFGKNTFHGLLLLRHVDELVKTGWPVLMSLSNKDFVGETLGVGLTER LEGTLAATALAAAAGVRMFRVHEVVATRRVLEMVASIQGTRPPTRTVRGLA
gene-sequence:>lcl|BSEQ0011515|Inactive dihydropteroate synthase 2 (folP2) GTGCAGTCAATGCTGTGCGGCCGGCCGGTCGCAGCGGATCGCCAACTGATCATGGCGATC GTCAACCGTACCCCGGATTCGTTCTATGACCGGGGCGCGACCTTCAGTGACGAGGCTGCT CGTGCTGCAGCGCACCGGGCCGTTGCGGAGGGCGCCGATGTCATCGATGTCGGCGGCGTT AAAGCAGGGCCTGGTCAGGGCGTTGACGTAGACACCGAGATCGCCCGGTTGGTTCCGTTC ATCGAATGGCTACGCAGCGCCTATACAGACCTGCTGATCAGCGTAGACACCTGGCGAGCA GAGGTAGCAAGACTGGCTTGCACTGCGGGCGCAGACCTGATCAACGACAGCTGGGGTGGA GCCGACCCGGCCATGCATGAGGTCGCCGCTGAGCTTGGCGCGGGCCTGGTGTGTTCGCAC ACCGGTGGCGCGCTGCCCCGCACGCGTCCCTTTCGGGTGAGTTACGGTACGACGACCCGC GGTGTGGTGGACGATGTGATTCGCCAGGTCACTGCAGCTGCCGAGCGCGCGGTCGCGGCC GGGGTAACCCGCGATTCGGTGTTGGTCGACCCGACCCACGATTTCGGCAAGAACACTTTC CACGGGCTGCTGCTGTTGCGTCATGTAGACGAACTTGTTAAGACCGGGTGGCCCGTGCTC ATGTCGTTGAGCAATAAGGACTTCGTCGGGGAGACTCTGGGCGTGGGTTTGACGGAACGG CTAGAGGGTACGTTGGCGGCCACTGCGTTGGCGGCGGCAGCTGGCGTCCGCATGTTTCGG GTGCACGAGGTCGTAGCGACCAGGCGGGTTCTGGAGATGGTGGCTTCGATCCAGGGGACG CGTCCCCCAACGCGCACGGTGAGGGGACTCGCATGA
pfams:PF00809Pterin_bind
go-classifiers:functiondihydropteroate synthase activityprocessfolic acid-containing compound biosynthetic process
id:BE0002086
name:Dihydropteroate synthase 1
organism:Mycobacterium leprae (strain TN)
action:inhibitor
Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V: Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis. 2006 Jan 15;42(2):238-41. Epub 2005 Dec 12.
Lee SB, Kim SK, Kang TJ, Chae GT, Chun JH, Shin HK, Kim JP, Ko YH, Kim NH: The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea. Ann Trop Med Parasitol. 2001 Jun;95(4):429-32.
Williams DL, Spring L, Harris E, Roche P, Gillis TP: Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother. 2000 Jun;44(6):1530-7.
Gengenbacher M, Xu T, Niyomrattanakit P, Spraggon G, Dick T: Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis. FEMS Microbiol Lett. 2008 Oct;287(1):128-35. doi: 10.1111/j.1574-6968.2008.01302.x. Epub 2008 Aug 1.
known-action:yes
name:Dihydropteroate synthase
general-function:Metal ion binding
specific-function:Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate, the immediate precursor of folate derivatives.
gene-name:folP1
locus:
cellular-location:
transmembrane-regions:
signal-regions:
theoretical-pi:5.63
molecular-weight:29447.355
chromosome-location:
organism:Mycobacterium leprae (strain TN)
external-identifiers:GenBank Gene DatabaseAB028658GenBank Protein Database5832717UniProtKBP0C0X1UniProt AccessionDHPS1_MYCLE
synonyms:2.5.1.15DHPSDihydropteroate pyrophosphorylasefolP
amino-acid-sequence:>lcl|BSEQ0011512|Dihydropteroate synthase MSLAPVQVIGVLNVTDNSFSDGGRYLDPDDAVQHGLAMVAEGAAIVDVGGESTRPGAIRT DPRVELSRIVPVVKELAAQGITVSIDTTRADVARAALQSGARIVNDVSGGRADPAMAPLV AEAGVAWVLMHWRLMSAERPYEAPNYRDVVAEVRADLLAGVDQAVAAGVDPGSLVIDPGL GFAKTGQHNWALLNALPELVATGVPILLGASRKRFLGRLLAGADGAVRPPDGRETATAVI SALAALHGAWGVRVHDVRASVDALKVVGAWLHAGPQIEKVRCDG
gene-sequence:>lcl|BSEQ0011513|Dihydropteroate synthase (folP1) GTGAGTTTGGCGCCAGTGCAGGTTATTGGGGTTTTGAACGTCACTGACAATTCGTTCTCA GATGGCGGACGTTACCTTGATCCTGACGATGCTGTCCAGCACGGCCTGGCAATGGTCGCG GAAGGCGCGGCGATTGTCGACGTCGGTGGCGAATCGACCCGGCCCGGTGCCATTAGGACC GATCCTCGAGTTGAACTCTCTCGTATCGTTCCTGTCGTAAAAGAACTTGCAGCACAGGGG ATTACAGTAAGTATCGATACTACGCGCGCTGATGTTGCACGGGCGGCGCTGCAAAGCGGC GCACGGATCGTCAACGATGTGTCTGGTGGGCGAGCAGATCCCGCGATGGCTCCTCTGGTG GCTGAAGCCGGTGTTGCGTGGGTGTTGATGCACTGGCGACTGATGTCGGCTGAACGGCCG TATGAGGCTCCGAATTACCGCGACGTGGTGGCTGAAGTGCGTGCCGACCTACTGGCTGGT GTCGATCAGGCTGTGGCCGCAGGTGTTGATCCTGGGAGTCTAGTGATCGATCCCGGGCTT GGATTCGCCAAGACGGGACAGCACAATTGGGCGCTGCTGAATGCGTTACCGGAGTTGGTG GCTACTGGGGTCCCGATTCTACTTGGCGCCTCGCGTAAACGGTTCCTGGGTAGGTTATTA GCTGGGGCTGATGGCGCGGTACGACCGCCGGACGGACGTGAGACGGCGACCGCGGTGATT TCCGCACTTGCTGCCCTACACGGGGCTTGGGGTGTTCGGGTGCACGATGTGCGTGCCTCG GTCGACGCACTCAAGGTCGTCGGGGCTTGGCTGCATGCTGGGCCGCAGATTGAAAAGGTT AGATGTGATGGCTGA
pfams:PF00809Pterin_bind
go-classifiers:functiondihydropteroate synthase activityfunctionmetal ion bindingprocessfolic acid biosynthetic processprocesstetrahydrofolate biosynthetic process

酶

BE0002362Cytochrome P450 3A5HumanssubstrateL162Flockhart Table of Drug Interactionshttps://drug-interactions.medicine.iu.edu/Main-Table.aspxunknownCytochrome P450 3A5Oxygen bindingCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.CYP3A57q21.1Endoplasmic reticulum membrane9.0957108.0657HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2638GenAtlasCYP3A5GenBank Gene DatabaseJ04813GenBank Protein Database181346Guide to Pharmacology1338UniProtKBP20815UniProt AccessionCP3A5_HUMAN1.14.14.1CYPIIIA5Cytochrome P450 HLp2Cytochrome P450-PCN3>lcl|BSEQ0004639|Cytochrome P450 3A5 MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG LLQPEKPIVLKVDSRDGTLSGE>lcl|BSEQ0016766|Cytochrome P450 3A5 (CYP3A5) ATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG CCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT GACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT GTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA GCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA AAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG AGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC ATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT CTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG TTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC CTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT TCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA ATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC AATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG AATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT GTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT CTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT AAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA CTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT GGAGAATGAPF00067p450componentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionaromatase activityfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingprocessalkaloid catabolic processprocessdrug catabolic processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic processBE0002638Cytochrome P450 3A4HumanssubstrateA1473510490933Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.A1841217586950Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT: Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther. 1995 Nov;58(5):556-66. doi: 10.1016/0009-9236(95)90176-0.L162Flockhart Table of Drug Interactionshttps://drug-interactions.medicine.iu.edu/Main-Table.aspxunknownCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic processBE0003606Dimethylaniline monooxygenase [N-oxide-forming] 3HumanssubstrateA41519515014Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.unknownDimethylaniline monooxygenase [N-oxide-forming] 3Trimethylamine monooxygenase activityInvolved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).FMO31q23-q25Microsome membrane7.8760032.9751HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:3771GenBank Gene DatabaseM83772GenBank Protein Database188631UniProtKBP31513UniProt AccessionFMO3_HUMAN1.14.13.8Dimethylaniline oxidase 3FMO 3FMO form 2FMO IIHepatic flavin-containing monooxygenase 3Trimethylamine monooxygenase>lcl|BSEQ0012507|Dimethylaniline monooxygenase [N-oxide-forming] 3 MGKKVAIIGAGVSGLASIRSCLEEGLEPTCFEKSNDIGGLWKFSDHAEEGRASIYKSVFS NSSKEMMCFPDFPFPDDFPNFMHNSKIQEYIIAFAKEKNLLKYIQFKTFVSSVNKHPDFA TTGQWDVTTERDGKKESAVFDAVMVCSGHHVYPNLPKESFPGLNHFKGKCFHSRDYKEPG VFNGKRVLVVGLGNSGCDIATELSRTAEQVMISSRSGSWVMSRVWDNGYPWDMLLVTRFG TFLKNNLPTAISDWLYVKQMNARFKHENYGLMPLNGVLRKEPVFNDELPASILCGIVSVK PNVKEFTETSAIFEDGTIFEGIDCVIFATGYSFAYPFLDESIIKSRNNEIILFKGVFPPL LEKSTIAVIGFVQSLGAAIPTVDLQSRWAAQVIKGTCTLPSMEDMMNDINEKMEKKRKWF GKSETIQTDYIVYMDELSSFIGAKPNIPWLFLTDPKLAMEVYFGPCSPYQFRLVGPGQWP GARNAILTQWDRSLKPMQTRVVGRLQKPCFFFHWLKLFAIPILLIAVFLVLT>lcl|BSEQ0012508|Dimethylaniline monooxygenase [N-oxide-forming] 3 (FMO3) ATGGGGAAGAAAGTGGCCATCATTGGAGCTGGTGTGAGTGGCTTGGCCTCCATCAGGAGC TGTCTGGAAGAGGGGCTGGAGCCCACCTGCTTTGAGAAGAGCAATGACATTGGGGGCCTG TGGAAATTTTCAGACCATGCAGAGGAGGGCAGGGCTAGCATTTACAAATCAGTCTTTTCC AACTCTTCCAAAGAGATGATGTGTTTCCCAGACTTCCCATTTCCCGATGACTTCCCCAAC TTTATGCACAACAGCAAGATCCAGGAATATATCATTGCATTTGCCAAAGAAAAGAACCTC CTGAAGTACATACAATTTAAGACATTTGTATCCAGTGTAAATAAACATCCTGATTTTGCA ACTACTGGCCAGTGGGATGTTACCACTGAAAGGGATGGTAAAAAAGAATCGGCTGTCTTT GATGCTGTAATGGTTTGTTCCGGACATCATGTGTATCCCAACCTACCAAAAGAGTCCTTT CCAGGACTAAACCACTTTAAAGGCAAATGCTTCCACAGCAGGGACTATAAAGAACCAGGT GTATTCAATGGAAAGCGTGTCCTGGTGGTTGGCCTGGGGAATTCGGGCTGTGATATTGCC ACAGAACTCAGCCGCACAGCAGAACAGGTCATGATCAGTTCCAGAAGTGGCTCCTGGGTG ATGAGCCGGGTCTGGGACAATGGTTATCCTTGGGACATGCTGCTCGTCACTCGATTTGGA ACCTTCCTCAAGAACAATTTACCGACAGCCATCTCTGACTGGTTGTACGTGAAGCAGATG AATGCAAGATTCAAGCATGAAAACTATGGCTTGATGCCTTTAAATGGAGTCCTGAGGAAA GAGCCTGTATTTAACGATGAGCTCCCAGCAAGCATTCTGTGTGGCATTGTGTCCGTAAAG CCTAACGTGAAGGAATTCACAGAGACCTCGGCCATTTTTGAGGATGGGACCATATTTGAG GGCATTGACTGTGTAATCTTTGCAACAGGGTATAGTTTTGCCTACCCCTTCCTTGATGAG TCTATCATCAAAAGCAGAAACAATGAGATCATTTTATTTAAAGGAGTATTTCCTCCTCTA CTTGAGAAGTCAACCATAGCAGTGATTGGCTTTGTCCAGTCCCTTGGGGCTGCCATTCCC ACAGTTGACCTCCAGTCCCGCTGGGCAGCACAAGTAATAAAGGGAACTTGTACTTTGCCT TCTATGGAAGACATGATGAATGATATTAATGAGAAAATGGAGAAAAAGCGCAAATGGTTT GGCAAAAGCGAGACCATACAGACAGATTACATTGTTTATATGGATGAACTCTCCTCCTTC ATTGGGGCAAAGCCCAACATCCCATGGCTGTTTCTCACAGATCCCAAATTGGCCATGGAA GTTTATTTTGGCCCTTGTAGTCCCTACCAGTTTAGGCTGGTGGGCCCAGGGCAGTGGCCA GGAGCCAGAAATGCCATACTGACCCAGTGGGACCGGTCGTTGAAACCCATGCAGACACGA GTGGTCGGGAGACTTCAGAAGCCTTGCTTCTTTTTCCATTGGCTGAAGCTCTTTGCAATT CCTATTCTGTTAATCGCTGTTTTCCTTGTGTTGACCTAAPF00743FMO-likecomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionflavin adenine dinucleotide bindingfunctionN,N-dimethylaniline monooxygenase activityfunctionNADP bindingfunctiontrimethylamine monooxygenase activityprocessdrug metabolic processprocessoxidation-reduction processprocesssmall molecule metabolic processprocessxenobiotic metabolic processBE0000017Prostaglandin G/H synthase 1HumanssubstrateA41519515014Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.unknownProstaglandin G/H synthase 1Prostaglandin-endoperoxide synthase activityConverts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells.PTGS19q32-q33.3Microsome membrane1-237.3968685.829HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:9604GenAtlasPTGS1GenBank Gene DatabaseM31822GenBank Protein Database387018Guide to Pharmacology1375UniProtKBP23219UniProt AccessionPGH1_HUMAN1.14.99.1COX-1COX1Cyclooxygenase-1PGH synthase 1PGHS-1PHS 1Prostaglandin H2 synthase 1Prostaglandin-endoperoxide synthase 1>lcl|BSEQ0036935|Prostaglandin G/H synthase 1 MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR TGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS NLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF LLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ YQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY ATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF DPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA LVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL VGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS PEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL>lcl|BSEQ0021254|Prostaglandin G/H synthase 1 (PTGS1) ATGAGCCGGAGTCTCTTGCTCTGGTTCTTGCTGTTCCTGCTCCTGCTCCCGCCGCTCCCC GTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC CAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC ACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA CTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG TTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCGCCTGGTACTCACAGTGCGCTCC AACCTTATCCCCAGTCCCCCCACCTACAACTCAGCACATGACTACATCAGCTGGGAGTCT TTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA CCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC CTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT GCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC AAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG TATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG TACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC CAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT GCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC ACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC AAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT GACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCATGGAGTTC AACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG TACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC CTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC CACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG CCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC GTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG GAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT ATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT CCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG GCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT GTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA PF03098An_peroxidasePF00008EGFcomponentcytoplasmcomponentendoplasmic reticulum membranecomponentextracellular exosomecomponentGolgi apparatuscomponentintracellular membrane-bounded organellecomponentnuclear envelopecomponentnucleuscomponentphotoreceptor outer segmentfunctiondioxygenase activityfunctionheme bindingfunctionlipid bindingfunctionmetal ion bindingfunctionperoxidase activityfunctionprostaglandin-endoperoxide synthase activityprocessagingprocessarachidonic acid metabolic processprocesscyclooxygenase pathwayprocessinflammatory responseprocesslearningprocesslipid metabolic processprocessmaintenance of blood-brain barrierprocessmemoryprocessnegative regulation of epinephrine secretionprocessnegative regulation of norepinephrine secretionprocesspositive regulation of smooth muscle contractionprocesspositive regulation of vasoconstrictionprocessprostaglandin biosynthetic processprocessregulation of blood pressureprocessregulation of cell proliferationprocessresponse to corticosteroneprocessresponse to fatty acidprocessresponse to organonitrogen compoundprocessresponse to oxidative stressprocesssensory perception of painprocesssmall molecule metabolic processprocessxenobiotic metabolic processBE0000262Prostaglandin G/H synthase 2HumanssubstrateA41519515014Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.unknownProstaglandin G/H synthase 2Prostaglandin-endoperoxide synthase activityConverts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.PTGS21q25.2-q25.3Microsome membrane1-177.4168995.6251HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:9605GenAtlasPTGS2GenBank Gene DatabaseL15326GenBank Protein Database291988Guide to Pharmacology1376UniProtKBP35354UniProt AccessionPGH2_HUMAN1.14.99.1COX-2COX2Cyclooxygenase-2PGH synthase 2PGHS-2PHS IIProstaglandin H2 synthase 2Prostaglandin-endoperoxide synthase 2>lcl|BSEQ0021832|Prostaglandin G/H synthase 2 MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER STEL>lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2) ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT TCGACTGAACTGTAGPF03098An_peroxidasePF00008EGFcomponentcaveolacomponentcytoplasmcomponentendoplasmic reticulumcomponentendoplasmic reticulum lumencomponentendoplasmic reticulum membranecomponentneuron projectioncomponentnucleuscomponentprotein complexfunctionarachidonate 15-lipoxygenase activityfunctionenzyme bindingfunctionheme bindingfunctionlipid bindingfunctionmetal ion bindingfunctionperoxidase activityfunctionprostaglandin-endoperoxide synthase activityprocessangiogenesisprocessarachidonic acid metabolic processprocessbone mineralizationprocessbrown fat cell differentiationprocesscellular response to ATPprocesscellular response to fluid shear stressprocesscellular response to hypoxiaprocesscellular response to mechanical stimulusprocesscellular response to UVprocesscyclooxygenase pathwayprocessdecidualizationprocessembryo implantationprocesshair cycleprocessinflammatory responseprocesslearningprocesslipoxygenase pathwayprocessmaintenance of blood-brain barrierprocessmemoryprocessmovement of cell or subcellular componentprocessNAD metabolic processprocessnegative regulation of calcium ion transportprocessnegative regulation of cell cycleprocessnegative regulation of cell proliferationprocessnegative regulation of smooth muscle contractionprocessnegative regulation of synaptic transmission, dopaminergicprocessnicotinamide metabolic processprocessovulationprocesspositive regulation of apoptotic processprocesspositive regulation of brown fat cell differentiationprocesspositive regulation of cell migration involved in sprouting angiogenesisprocesspositive regulation of fever generationprocesspositive regulation of fibroblast growth factor productionprocesspositive regulation of NF-kappaB import into nucleusprocesspositive regulation of nitric oxide biosynthetic processprocesspositive regulation of platelet-derived growth factor productionprocesspositive regulation of prostaglandin biosynthetic processprocesspositive regulation of smooth muscle cell proliferationprocesspositive regulation of smooth muscle contractionprocesspositive regulation of synaptic plasticityprocesspositive regulation of synaptic transmission, glutamatergicprocesspositive regulation of transforming growth factor beta productionprocesspositive regulation of vascular endothelial growth factor productionprocesspositive regulation of vasoconstrictionprocessprostaglandin biosynthetic processprocessprostaglandin metabolic processprocessregulation of blood pressureprocessregulation of inflammatory responseprocessresponse to drugprocessresponse to estradiolprocessresponse to fatty acidprocessresponse to fructoseprocessresponse to glucocorticoidprocessresponse to lipopolysaccharideprocessresponse to lithium ionprocessresponse to manganese ionprocessresponse to oxidative stressprocessresponse to tumor necrosis factorprocessresponse to vitamin Dprocesssensory perception of painprocesssmall molecule metabolic processprocessvitamin metabolic processprocesswater-soluble vitamin metabolic processBE0002887Cytochrome P450 2C8HumanssubstrateA41519515014Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.A18420817286541Gil JP, Gil Berglund E: CYP2C8 and antimalaria drug efficacy. Pharmacogenomics. 2007 Feb;8(2):187-98. doi: 10.2217/14622416.8.2.187.A1474210901692Winter HR, Wang Y, Unadkat JD: CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.unknownCytochrome P450 2C8Steroid hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti-cancer drug paclitaxel (taxol).CYP2C810q23.33Endoplasmic reticulum membrane8.6255824.27510HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2622GenAtlasCYP2C8GenBank Gene DatabaseM17397Guide to Pharmacology1325UniProtKBP10632UniProt AccessionCP2C8_HUMAN1.14.14.1CYPIIC8Cytochrome P450 form 1Cytochrome P450 IIC2Cytochrome P450 MP-12Cytochrome P450 MP-20S-mephenytoin 4-hydroxylase>lcl|BSEQ0005650|Cytochrome P450 2C8 MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP PSYQICFIPV>lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8) ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA CCCTCATACCAGATCTGCTTCATCCCTGTCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionarachidonic acid epoxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessarachidonic acid metabolic processprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessomega-hydroxylase P450 pathwayprocessorganic acid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocessxenobiotic metabolic processBE0003536Cytochrome P450 2C19HumanssubstrateA3864119998329Ganesan S, Sahu R, Walker LA, Tekwani BL: Cytochrome P450-dependent toxicity of dapsone in human erythrocytes. J Appl Toxicol. 2010 Apr;30(3):271-5. doi: 10.1002/jat.1493.A3864221422237Abouraya M, Sacco JC, Hayes K, Thomas S, Kitchens CS, Trepanier LA: Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity. J Clin Pharmacol. 2012 Feb;52(2):272-8. doi: 10.1177/0091270010393343.unknownCytochrome P450 2C19Steroid hydroxylase activityResponsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.CYP2C1910q24.1-q24.3Endoplasmic reticulum membrane7.4255930.54510HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2621GenBank Gene DatabaseM61854GenBank Protein Database181344Guide to Pharmacology1328UniProtKBP33261UniProt AccessionCP2CJ_HUMAN(R)-limonene 6-monooxygenase(S)-limonene 6-monooxygenase(S)-limonene 7-monooxygenase1.14.13.-CYPIIC17CYPIIC19Cytochrome P450-11ACytochrome P450-254CMephenytoin 4-hydroxylase>lcl|BSEQ0020694|Cytochrome P450 2C19 MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP PFYQLCFIPV>lcl|BSEQ0020695|Cytochrome P450 2C19 (CYP2C19) ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunction(R)-limonene 6-monooxygenase activityfunction(S)-limonene 6-monooxygenase activityfunction(S)-limonene 7-monooxygenase activityfunctionarachidonic acid epoxygenase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessarachidonic acid metabolic processprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessheterocycle metabolic processprocessmonoterpenoid metabolic processprocessomega-hydroxylase P450 pathwayprocessoxidation-reduction processprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic processBE0003607Arylamine N-acetyltransferase 2HumanssubstrateA41519515014Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.unknownArylamine N-acetyltransferase 2Arylamine n-acetyltransferase activityParticipates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.NAT28p22Cytoplasm5.6733542.2358HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:7646GenBank Gene DatabaseD90040GenBank Protein Database219412UniProtKBP11245UniProt AccessionARY2_HUMAN2.3.1.5AAC2Arylamide acetylase 2N-acetyltransferase type 2NAT-2PNATPolymorphic arylamine N-acetyltransferase>lcl|BSEQ0006940|Arylamine N-acetyltransferase 2 MDIEAYFERIGYKNSRNKLDLETLTDILEHQIRAVPFENLNMHCGQAMELGLEAIFDHIV RRNRGGWCLQVNQLLYWALTTIGFQTTMLGGYFYIPPVNKYSTGMVHLLLQVTIDGRNYI VDAGSGSSSQMWQPLELISGKDQPQVPCIFCLTEERGIWYLDQIRREQYITNKEFLNSHL LPKKKHQKIYLFTLEPRTIEDFESMNTYLQTSPTSSFITTSFCSLQTPEGVYCLVGFILT YRKFNYKDNTDLVEFKTLTEEEVEEVLKNIFKISLGRNLVPKPGDGSLTI>lcl|BSEQ0012509|Arylamine N-acetyltransferase 2 (NAT2) ATGGACATTGAAGCATATTTTGAAAGAATTGGCTATAAGAACTCTAGGAACAAATTGGAC TTGGAAACATTAACTGACATTCTTGAGCACCAGATCCGGGCTGTTCCCTTTGAGAACCTT AACATGCATTGTGGGCAAGCCATGGAGTTGGGCTTAGAGGCTATTTTTGATCACATTGTA AGAAGAAACCGGGGTGGGTGGTGTCTCCAGGTCAATCAACTTCTGTACTGGGCTCTGACC ACAATCGGTTTTCAGACCACAATGTTAGGAGGGTATTTTTACATCCCTCCAGTTAACAAA TACAGCACTGGCATGGTTCACCTTCTCCTGCAGGTGACCATTGACGGCAGGAATTACATT GTCGATGCTGGGTCTGGAAGCTCCTCCCAGATGTGGCAGCCTCTAGAATTAATTTCTGGG AAGGATCAGCCTCAGGTGCCTTGCATTTTCTGCTTGACAGAAGAGAGAGGAATCTGGTAC CTGGACCAAATCAGGAGAGAGCAGTATATTACAAACAAAGAATTTCTTAATTCTCATCTC CTGCCAAAGAAGAAACACCAAAAAATATACTTATTTACGCTTGAACCTCGAACAATTGAA GATTTTGAGTCTATGAATACATACCTGCAGACGTCTCCAACATCTTCATTTATAACCACA TCATTTTGTTCCTTGCAGACCCCAGAAGGGGTTTACTGTTTGGTGGGCTTCATCCTCACC TATAGAAAATTCAATTATAAAGACAATACAGATCTGGTCGAGTTTAAAACTCTCACTGAG GAAGAGGTTGAAGAAGTGCTGAGAAATATATTTAAGATTTCCTTGGGGAGAAATCTCGTG CCCAAACCTGGTGATGGATCCCTTACTATTTAGPF00797Acetyltransf_2componentcytosolfunctionarylamine N-acetyltransferase activityprocesssmall molecule metabolic processprocessxenobiotic metabolic processBE0002793Cytochrome P450 2C9HumanssubstrateinducerA41519515014Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.A3934112386124Hutzler JM, Kolwankar D, Hummel MA, Tracy TS: Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos. 2002 Nov;30(11):1194-200.A18326611408370Hutzler JM, Hauer MJ, Tracy TS: Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos. 2001 Jul;29(7):1029-34.unknownCytochrome P450 2C9Steroid hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.CYP2C910q24Endoplasmic reticulum membrane7.9955627.36510HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2623GenAtlasCYP2C9GenBank Gene DatabaseAY341248Guide to Pharmacology1326UniProtKBP11712UniProt AccessionCP2C9_HUMAN(R)-limonene 6-monooxygenase(S)-limonene 6-monooxygenase(S)-limonene 7-monooxygenase1.14.13.-Cholesterol 25-hydroxylaseCYP2C10CYPIIC9Cytochrome P-450MPCytochrome P450 MP-4Cytochrome P450 MP-8Cytochrome P450 PB-1S-mephenytoin 4-hydroxylase>lcl|BSEQ0005471|Cytochrome P450 2C9 MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP PFYQLCFIPV>lcl|BSEQ0016893|Cytochrome P450 2C9 (CYP2C9) ATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA AATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT GAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG GCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC ATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG TTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT CCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG AAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT CAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT GAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG ACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA GCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC CTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC ATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA TTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG AAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG GCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT CTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG CCCTTCTACCAGCTGTGCTTCATTCCTGTCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunction(R)-limonene 6-monooxygenase activityfunction(S)-limonene 6-monooxygenase activityfunction(S)-limonene 7-monooxygenase activityfunctionarachidonic acid epoxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctiondrug bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessarachidonic acid metabolic processprocesscellular amide metabolic processprocessdrug catabolic processprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessmonocarboxylic acid metabolic processprocessmonoterpenoid metabolic processprocessomega-hydroxylase P450 pathwayprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid metabolic processprocessurea metabolic processprocessxenobiotic metabolic processunknownBE0003612Cytochrome P450 3A7HumanssubstrateL162Flockhart Table of Drug Interactionshttps://drug-interactions.medicine.iu.edu/Main-Table.aspxunknownCytochrome P450 3A7Oxygen bindingCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.CYP3A77q21-q22.1Endoplasmic reticulum membrane9.5957525.037HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2640GenBank Gene DatabaseD00408GenBank Protein Database220149UniProtKBP24462UniProt AccessionCP3A7_HUMAN1.14.14.1CYPIIIA7Cytochrome P450-HFLA>lcl|BSEQ0006949|Cytochrome P450 3A7 MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG GLLLTEKPIVLKAESRDETVSGA>lcl|BSEQ0019448|Cytochrome P450 3A7 (CYP3A7) ATGGATCTCATCCCAAACTTGGCCGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGATA CTCCTCTATCTATATGGAACCCGTACACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATGCTTTGTCCTTCCGTAAGGGCTATTGGACGTTT GACATGGAATGTTATAAAAAGTATAGAAAAGTCTGGGGTATTTATGACTGTCAACAGCCT ATGCTGGCTATCACAGATCCCGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTCGGGCCAGTGGGATTTATGAAAAATGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGAATACGATCATTGCTGTCTCCAACATTCACCAGCGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAACACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAGCATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTAATCCATTAGATCCATTCGTT CTCTCAATAAAAGTCTTTCCATTCCTTACCCCAATTCTTGAAGCATTAAATATCACTGTG TTTCCAAGAAAAGTTATAAGTTTTCTAACAAAATCTGTAAAACAGATAAAAGAAGGTCGC CTCAAAGAGACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT TCAAAAGACTCTGAGACCCACAAAGCTCTGTCTGATCTGGAGCTCATGGCCCAATCAATT ATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATATATGAA CTGGCCACTCACCCTGATGTCCAGCAGAAAGTGCAGAAGGAAATTGATACAGTTTTACCC AATAAGGCACCACCCACCTATGATACTGTGCTACAGTTGGAGTATCTTGACATGGTGGTG AATGAAACACTCAGATTATTCCCAGTTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT GTTGAAATCAATGGGATGTTTATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGTT CTTCATCATGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGGTTCAGT AAAAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA AACTGCATTGGCATGAGGTTTGCTCTCGTGAACATGAAACTTGCTCTAGTCAGAGTCCTT CAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTACGCTTTGGA GGACTTCTTCTAACAGAAAAACCCATTGTTCTAAAGGCTGAGTCAAGGGATGAGACCTTT GTAGATATGGAGCCCATTCACATGGACTTTTTAAGAAGCTTGGCATTCCAGGGCCCACAC CTCTGCTTTTTTTGGGAACTACTTTGTCCTACCATCAGATCCCGCTGAPF00067p450componentendoplasmic reticulum membranefunctionaromatase activityfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxygen bindingprocesssmall molecule metabolic processprocessxenobiotic metabolic processBE0003533Cytochrome P450 2E1HumanssubstrateA1841217586950Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT: Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther. 1995 Nov;58(5):556-66. doi: 10.1016/0009-9236(95)90176-0.unknownCytochrome P450 2E1Steroid hydroxylase activityMetabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.CYP2E110q24.3-qterEndoplasmic reticulum membrane8.2256848.4210HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2631GenBank Gene DatabaseJ02625GenBank Protein Database181360Guide to Pharmacology1330UniProtKBP05181UniProt AccessionCP2E1_HUMAN1.14.13.-4-nitrophenol 2-hydroxylaseCYP2ECYPIIE1Cytochrome P450-J>lcl|BSEQ0012460|Cytochrome P450 2E1 MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC IPPRYKLCVIPRS>lcl|BSEQ0012461|Cytochrome P450 2E1 (CYP2E1) ATGTCTGCCCTCGGAGTCACCGTGGCCCTGCTGGTGTGGGCGGCCTTCCTCCTGCTGGTG TCCATGTGGAGGCAGGTGCACAGCAGCTGGAATCTGCCCCCAGGCCCTTTCCCGCTTCCC ATCATCGGGAACCTCTTCCAGTTGGAATTGAAGAATATTCCCAAGTCCTTCACCCGGTTG GCCCAGCGCTTCGGGCCGGTGTTCACGCTGTACGTGGGCTCGCAGCGCATGGTGGTGATG CACGGCTACAAGGCGGTGAAGGAAGCGCTGCTGGACTACAAGGACGAGTTCTCGGGCAGA GGCGACCTCCCCGCGTTCCATGCGCACAGGGACAGGGGAATCATTTTTAATAATGGACCT ACCTGGAAGGACATCCGGCGGTTTTCCCTGACCACCCTCCGGAACTATGGGATGGGGAAA CAGGGCAATGAGAGCCGGATCCAGAGGGAGGCCCACTTCCTGCTGGAAGCACTCAGGAAG ACCCAAGGCCAGCCTTTCGACCCCACCTTCCTCATCGGCTGCGCGCCCTGCAACGTCATA GCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTCTAAGGCTGATG TATTTGTTTAATGAGAACTTCCACCTACTCAGCACTCCCTGGCTCCAGCTTTACAATAAT TTTCCCAGCTTTCTACACTACTTGCCTGGAAGCCACAGAAAAGTCATAAAAAATGTGGCT GAAGTAAAAGAGTATGTGTCTGAAAGGGTGAAGGAGCACCATCAATCTCTGGACCCCAAC TGTCCCCGGGACCTCACCGACTGCCTGCTCGTGGAAATGGAGAAGGAAAAGCACAGTGCA GAGCGCTTGTACACAATGGACGGTATCACCGTGACTGTGGCCGACCTGTTCTTTGCGGGG ACAGAGACCACCAGCACAACTCTGAGATATGGGCTCCTGATTCTCATGAAATACCCTGAG ATCGAAGAGAAGCTCCATGAAGAAATTGACAGGGTGATTGGGCCAAGCCGAATCCCTGCC ATCAAGGATAGGCAAGAGATGCCCTACATGGATGCTGTGGTGCATGAGATTCAGCGGTTC ATCACCCTCGTGCCCTCCAACCTGCCCCATGAAGCAACCCGAGACACCATTTTCAGAGGA TACCTCATCCCCAAGGGCACAGTCGTAGTGCCAACTCTGGACTCTGTTTTGTATGACAAC CAAGAATTTCCTGATCCAGAAAAGTTTAAGCCAGAACACTTCCTGAATGAAAATGGAAAG TTCAAGTACAGTGACTATTTCAAGCCATTTTCCACAGGAAAACGAGTGTGTGCTGGAGAA GGCCTGGCTCGCATGGAGTTGTTTCTTTTGTTGTGTGCCATTTTGCAGCATTTTAATTTG AAGCCTCTCGTTGACCCAAAGGATATCGACCTCAGCCCTATACATATTGGGTTTGGCTGT ATCCCACCACGTTACAAACTCTGTGTCATTCCCCGCTCATGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentGolgi membranecomponentintracellular membrane-bounded organellecomponentintrinsic component of endoplasmic reticulum membranecomponentmitochondrionfunctionarachidonic acid epoxygenase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessheterocycle metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessresponse to ethanolprocessresponse to organonitrogen compoundprocessresponse to ozoneprocesssmall molecule metabolic processprocesssteroid metabolic processprocesstriglyceride metabolic processprocessxenobiotic metabolic processBE0001075MyeloperoxidaseHumanssubstrateA41519515014Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.unknownMyeloperoxidasePeroxidase activityPart of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.MPO17q23.1Lysosome1-489.1483867.7117HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:7218GenAtlasMPOGenBank Gene DatabaseJ02694GenBank Protein Database189040Guide to Pharmacology2789UniProtKBP05164UniProt AccessionPERM_HUMAN1.11.2.2MPO>lcl|BSEQ0002139|Myeloperoxidase MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS NSYPRDFVNCSTLPALNLASWREAS>lcl|BSEQ0016304|Myeloperoxidase (MPO) ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC TGGAGGGAAGCCTCCTAGPF03098An_peroxidasecomponentazurophil granulecomponentextracellular exosomecomponentextracellular spacecomponentlysosomecomponentmitochondrioncomponentnucleuscomponentsecretory granulefunctionchromatin bindingfunctionheme bindingfunctionheparin bindingfunctionmetal ion bindingfunctionperoxidase activityprocessdefense responseprocessdefense response to fungusprocesshydrogen peroxide catabolic processprocesshypochlorous acid biosynthetic processprocesslow-density lipoprotein particle remodelingprocessnegative regulation of apoptotic processprocessnegative regulation of growth of symbiont in hostprocessoxidation-reduction processprocessremoval of superoxide radicalsprocessrespiratory burst involved in defense responseprocessresponse to oxidative stressprocessresponse to yeastBE0003611Cytochrome P450 2C18HumanssubstrateA1474210901692Winter HR, Wang Y, Unadkat JD: CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.unknownCytochrome P450 2C18Steroid hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.CYP2C1810q24Endoplasmic reticulum membrane7.2255710.07510HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2620GenBank Gene DatabaseM61853Guide to Pharmacology1327UniProtKBP33260UniProt AccessionCP2CI_HUMAN1.14.14.1CYPIIC18Cytochrome P450-6b/29c>lcl|BSEQ0006947|Cytochrome P450 2C18 MDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKV YGPVFTVYFGLKPIVVLHGYEAVKEALIDHGEEFSGRGSFPVAEKVNKGLGILFSNGKRW KEIRRFCLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICS VIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYI KSYVLERIKEHQESLDMNSARDFIDCFLIKMEQEKHNQQSEFTVESLIATVTDMFGAGTE TTSTTLRYGLLLLLKYPEVTAKVQEEIECVVGRNRSPCMQDRSHMPYTDAVVHEIQRYID LLPTNLPHAVTCDVKFKNYLIPKGTTIITSLTSVLHNDKEFPNPEMFDPGHFLDKSGNFK KSDYFMPFSAGKRMCMGEGLARMELFLFLTTILQNFNLKSQVDPKDIDITPIANAFGRVP PLYQLCFIPV>lcl|BSEQ0012511|Cytochrome P450 2C18 (CYP2C18) ATGGATCCAGCTGTGGCTCTGGTGCTCTGTCTCTCCTGTTTGTTTCTCCTTTCACTCTGG AGGCAGAGCTCTGGAAGAGGGAGGCTCCCGTCTGGCCCCACTCCTCTCCCGATTATTGGA AATATCCTGCAGTTAGATGTTAAGGACATGAGCAAATCCTTAACCAATTTCTCAAAAGTC TATGGCCCTGTGTTCACTGTGTATTTTGGCCTGAAGCCCATTGTGGTGTTGCATGGATAT GAAGCAGTGAAGGAGGCCCTGATTGATCATGGAGAGGAGTTTTCTGGAAGAGGAAGTTTT CCAGTGGCTGAAAAAGTTAACAAAGGACTTGGAATCCTTTTCAGCAATGGAAAGAGATGG AAGGAGATCCGGCGTTTCTGCCTCATGACTCTGCGGAATTTTGGGATGGGGAAGAGGAGC ATCGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAT GCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCT GTTATTTTCCATGATCGATTTGATTATAAAGATCAGAGGTTTCTTAACTTGATGGAAAAA TTCAATGAAAACCTCAGGATTCTGAGCTCTCCATGGATCCAGGTCTGCAATAATTTCCCT GCTCTCATCGATTATCTCCCAGGAAGTCATAATAAAATAGCTGAAAATTTTGCTTACATT AAAAGTTATGTATTGGAGAGAATAAAAGAACATCAAGAATCCCTGGACATGAACAGTGCT CGGGACTTTATTGATTGTTTCCTGATCAAAATGGAACAGGAAAAGCACAATCAACAGTCT GAATTTACTGTTGAAAGCTTGATAGCCACTGTAACTGATATGTTTGGGGCTGGAACAGAG ACAACGAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGTACCCAGAGGTCACA GCTAAAGTCCAGGAAGAGATTGAATGTGTAGTTGGCAGAAACCGGAGCCCCTGTATGCAG GACAGGAGTCACATGCCCTACACAGATGCTGTGGTGCACGAGATCCAGAGATACATTGAC CTCCTCCCCACCAACCTGCCCCATGCAGTGACCTGTGATGTTAAATTCAAAAACTACCTC ATCCCCAAGGGCACGACCATAATAACATCCCTGACTTCTGTGCTGCACAATGACAAAGAA TTCCCCAACCCAGAGATGTTTGACCCTGGCCACTTTCTGGATAAGAGTGGCAACTTTAAG AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGGATGTGTATGGGAGAGGGCCTG GCCCGCATGGAGCTGTTTTTATTCCTGACCACCATTTTGCAGAACTTTAACCTGAAATCT CAGGTTGACCCAAAGGATATTGACATCACCCCCATTGCCAATGCATTTGGTCGTGTGCCA CCCTTGTACCAGCTCTGCTTCATTCCTGTCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionarachidonic acid epoxygenase activityfunctionaromatase activityfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenfunctionoxygen bindingfunctionsteroid hydroxylase activityprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessoxidation-reduction processprocesssmall molecule metabolic processprocessxenobiotic metabolic process

载体

运输工具

药物反应

reactions:1
left-element--drugbank-id:DB00250
left-element--name:Dapsone
right-element--drugbank-id:DBMET00301
right-element--name:dapsone hydroxylamine
enzymes--drugbank-id:BE0002793
enzymes--name:Cytochrome P450 2C9
enzymes--uniprot-id:P11712
enzymes--drugbank-id:BE0003533
enzymes--name:Cytochrome P450 2E1
enzymes--uniprot-id:P05181
enzymes--drugbank-id:BE0002638
enzymes--name:Cytochrome P450 3A4
enzymes--uniprot-id:P08684
enzymes--drugbank-id:BE0001075
enzymes--name:Myeloperoxidase
enzymes--uniprot-id:P05164
enzymes--drugbank-id:BE0000262
enzymes--name:Prostaglandin G/H synthase 2
enzymes--uniprot-id:P35354
reactions:1
left-element--drugbank-id:DB00250
left-element--name:Dapsone
right-element--drugbank-id:DBMET00014
right-element--name:Monoacetyldapsone
enzymes--drugbank-id:BE0003607
enzymes--name:Arylamine N-acetyltransferase 2
enzymes--uniprot-id:P11245
reactions:2
left-element--drugbank-id:DBMET00301
left-element--name:dapsone hydroxylamine
right-element--drugbank-id:DBMET01043
right-element--name:Nitroso-dapsone
reactions:3
left-element--drugbank-id:DBMET01043
left-element--name:Nitroso-dapsone
right-element--drugbank-id:DBMET01045
right-element--name:Dapsone mercaptal intermediate
reactions:4
left-element--drugbank-id:DBMET01045
left-element--name:Dapsone mercaptal intermediate
right-element--drugbank-id:DBMET01046
right-element--name:Dapsone GSH conjugate

效应

不良反应